

NATIONAL QUALITY FORUM

Measure Submission and Evaluation Worksheet 5.0

This form contains the information submitted by measure developers/stewards, organized according to NQF's measure evaluation criteria and process. The evaluation criteria, evaluation guidance documents, and a blank online submission form are available on the [submitting standards web page](#).

NQF #: 1729 NQF Project: Patient Safety Measures-Complications Project
(for Endorsement Maintenance Review)
Original Endorsement Date: Most Recent Endorsement Date:
BRIEF MEASURE INFORMATION
De.1 Measure Title: Polytherapy with Oral Antipsychotics
Co.1.1 Measure Steward: Centers for Medicare & Medicaid Services
De.2 Brief Description of Measure: The percentage of individuals 18 years of age and older with persistent use of 2 or more oral antipsychotic medications.
2a1.1 Numerator Statement: Individuals in the denominator who are prescribed 2 or more concurrent routinely scheduled antipsychotic medications.
2a1.4 Denominator Statement: Individuals 18 years of age and older who were prescribed at least one routinely scheduled oral antipsychotic medication during the measurement period.
2a1.8 Denominator Exclusions: • Individuals who received a dispensing for clozapine any time during the measurement period • Individuals who died during the measurement period
1.1 Measure Type: Process
2a1. 25-26 Data Source: Administrative claims, Electronic Clinical Data : Pharmacy
2a1.33 Level of Analysis: Clinician : Group/Practice, Health Plan, Population : State
1.2-1.4 Is this measure paired with another measure? No
De.3 If included in a composite, please identify the composite measure (title and NQF number if endorsed):

STAFF NOTES (issues or questions regarding any criteria)
Comments on Conditions for Consideration:
Is the measure untested? Yes <input type="checkbox"/> No <input type="checkbox"/> If untested, explain how it meets criteria for consideration for time-limited endorsement:
1a. Specific national health goal/priority identified by DHHS or NPP addressed by the measure (check De.5): 5. Similar/related endorsed or submitted measures (check 5.1): Other Criteria:
Staff Reviewer Name(s):

1. IMPACT, OPPORTUNITY, EVIDENCE - IMPORTANCE TO MEASURE AND REPORT
Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All three subcriteria must be met to pass this criterion. See guidance on evidence . Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)

1a. High Impact: H M L I

(The measure directly addresses a specific national health goal/priority identified by DHHS or NPP, or some other high impact aspect of healthcare.)

De.4 Subject/Topic Areas (Check all the areas that apply): Mental Health

De.5 Cross Cutting Areas (Check all the areas that apply): Safety : Medication Safety

1a.1 Demonstrated High Impact Aspect of Healthcare: High resource use

1a.2 If "Other," please describe:

1a.3 Summary of Evidence of High Impact (Provide epidemiologic or resource use data):

The majority of antipsychotic drugs prescribed for seniors are paid for by Medicare (Donohue, 2006). The utilization of antipsychotic medications under Medicare Part D is rising dramatically (Chen et al, 2008). Treatment guidelines support monotherapy with antipsychotic medications (Lehman et al, 2004); a clear role for the use of polytherapy has not been defined. The prescribing of multiple antipsychotic medications is an increasing trend, occurring in up to 40% of inpatients and 11%-35% of outpatients receiving these medications (Kogut, Yam, & Dufresne, 2005; Covell, Jackson, Evans, & Essock, 2002; Ganguly, Kotzan, Miller, Kennedy, & Martin, 2004). In the majority of clinical circumstances, the use of antipsychotic polytherapy increases the risk of side effects without providing additional benefit (Stahl & Grady, 2004). One review concluded that among patients who had not failed adequate trials of monotherapy, the use of polytherapy was associated with greater side effects without clear improvements in patient outcomes (Goren et al, 2008). The reduction in use of polytherapy holds promise for reducing the direct cost of therapy of these expensive medications, while also potentially reducing direct and indirect costs attributed to drug interactions and untoward side effects consequent to additive pharmacologic effects. This is a particular concern among the elderly, where the effects of these medications are less well understood (Pollock, Forsyth, & Bies, 2009). While the cost-effectiveness of antipsychotics has been established for labeled indications when used as monotherapy (Davies, et al, 2008; Jerrell, 2002), evidence is lacking to support the cost-effectiveness of atypical antipsychotics when used in polytherapy or for off-label uses (e.g., agitation).

In conclusion, the high frequency of antipsychotic polypharmacy, its high direct costs, and the safety concerns associated with evidence of higher incidence of serious side effects provide support for a polytherapy measure for antipsychotics.

1a.4 Citations for Evidence of High Impact cited in 1a.3: Chen, H., Nwangwu, A., Aparasu, R., Essien, E., Sun, S., & Lee, K. (2008). The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatr Serv, 59, 1191-7.

Covell, N.H., Jackson, C.T., Evans, A.C., Essock, S.M. (2002). Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull, 28,17-29.

Davies, A., Vardeva, K., Loze, J.Y., & L'Italien, G.J., Sennfalt K, van Baardewijk M. (2008). Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK*. Curr Med Res Opin, 24(11), 3275-3285.

Donohue J. (2006). Mental health in the Medicare Part D drug benefit: a new regulatory model? Health Aff. (Millwood),25, 707-19.

Ganguly, R., Kotzan, J.A., Miller, L.S., Kennedy, K., & Martin, B.C. (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry, 65,1377-88.

Goren, J.L., Parks, J.J., Ghinassi, F.A., et al. (2008). When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf, 34, 571-82.

Jerrell, J.M. (2002). Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull, 28, 589-605.

Kogut, S.J., Yam, F., & Dufresne, R. (2005). Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm, 11, 17-24.

Lehman, A.F., Lieberman, J.A., Dixon, L.B., et al. (2004). Practice guideline for the treatment of patients with schizophrenia, second

edition. Am J Psychiatry, 161, 1-56.

Pollock, B., Forsyth, C., & Bies, R. (2009). The critical role of clinical pharmacology in geriatric psychopharmacology. Clin Pharmacol Ther, 85, 89-93.

Stahl, S.M. & Grady, M.M. (2004). A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem, 11, 313-27.

1b. Opportunity for Improvement: H M L I

(*There is a demonstrated performance gap - variability or overall less than optimal performance*)

1b.1 Briefly explain the benefits (improvements in quality) envisioned by use of this measure:

- In the United States in 2008, an estimated 5.1% (1,526,192/29,735,792) Medicare beneficiaries enrolled in a Part D plan had at least one routinely prescribed oral antipsychotic medication during the measurement period.
- In the United States in 2008, an estimated 8.9% (135,447/1,526,192) of Medicare beneficiaries with at least one routinely prescribed oral antipsychotic medication were classified as having oral antipsychotic polytherapy.
- Based on unpublished proprietary data for 2008, the cost of an oral antipsychotic medication was estimated as \$1,509 per year (in 2008 dollars).
- If the overall national measure rate could be decreased from 8.9% (measure rate of the eight-state sample) to 2.1% (10th percentile for Part D plans in the eight-state sample):
 - 103,397 fewer Medicare beneficiaries would be on polytherapy with oral antipsychotic medication in the United States each year.
 - The direct medical costs of the antipsychotic medication, \$156,026,525 (in 2008 dollars) would be avoided for these individuals.
- This does not account for the costs of quality improvement interventions.

1b.2 Summary of Data Demonstrating Performance Gap (Variation or overall less than optimal performance across providers):

[**For Maintenance** – Descriptive statistics for performance results for this measure - distribution of scores for measured entities by quartile/decile, mean, median, SD, min, max, etc.]

Antipsychotic polytherapy is a prevalent phenomenon, particularly among the dually-enrolled population under 65 years of age, with rates of use ranging from 5% to 20% (Kogut, Yam, & Dufresne, 2005; Gilmer, Dolder, Folsom, Mastin, & Jeste, 2007; Kreyenbuhl, Valenstein, McCarthy, Ganoczy, & Blow, 2006).

1b.3 Citations for Data on Performance Gap: [**For Maintenance** – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]

Kogut, S.J., Yam, F., & Dufresne, R. (2005). Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm, 11, 17-24.

Gilmer, T.P., Dolder, C.R., Folsom, D.P., Mastin, W., Jeste, D.V. (2007). Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv, 58, 1007-10.

Kreyenbuhl, J., Valenstein, M., McCarthy, J.F., Ganoczy, D., Blow, F.C. (2006). Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res, 84, 90-9.

1b.4 Summary of Data on Disparities by Population Group: [**For Maintenance** – Descriptive statistics for performance results for this measure by population group]

Reference disparities section.

1b.5 Citations for Data on Disparities Cited in 1b.4: [**For Maintenance** – Description of the data or sample for measure results reported in 1b.4 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]

Not available

1c. Evidence (Measure focus is a health outcome OR meets the criteria for quantity, quality, consistency of the body of evidence.)
Is the measure focus a health outcome? Yes No If not a health outcome, rate the body of evidence.

Quantity: H M L I Quality: H M L I Consistency: H M L I

Quantity	Quality	Consistency	Does the measure pass subcriterion1c?			
M-H	M-H	M-H	Yes <input type="checkbox"/>			
L	M-H	M	Yes <input type="checkbox"/> IF additional research unlikely to change conclusion that benefits to patients outweigh harms: otherwise No <input type="checkbox"/>			
M-H	L	M-H	Yes <input type="checkbox"/> IF potential benefits to patients clearly outweigh potential harms: otherwise No <input type="checkbox"/>			
L-M-H	L-M-H	L	No <input type="checkbox"/>			
Health outcome – rationale supports relationship to at least one healthcare structure, process, intervention, or service	Does the measure pass subcriterion1c? Yes <input type="checkbox"/> IF rationale supports relationship					
<p>1c.1 Structure-Process-Outcome Relationship (<i>Briefly state the measure focus, e.g., health outcome, intermediate clinical outcome, process, structure; then identify the appropriate links, e.g., structure-process-health outcome; process- health outcome; intermediate clinical outcome-health outcome</i>):</p> <p>The measure focus is on the process of patients filling more than one antipsychotic medication concomitantly for 90 days or more. The process leads to undesirable outcomes as follows: patient filling more than one antipsychotic medication >> patient taking antipsychotic medications as prescribed >> adverse drug events and increased costs without improved effectiveness.</p>						
<p>1c.2-3 Type of Evidence (<i>Check all that apply</i>):</p> <p>Clinical Practice Guideline, Systematic review of body of evidence (other than within guideline development)</p>						
<p>1c.4 Directness of Evidence to the Specified Measure (<i>State the central topic, population, and outcomes addressed in the body of evidence and identify any differences from the measure focus and measure target population</i>):</p> <p>Reviews of the collective evidence base have shown that the common practice of combining antipsychotics to optimize treatment response lacks empirical support (Freudenreich, & Goff, 2002; Goodwin et al. 2009; Stahl, & Grady, 2004; Tranulis et al. 2008). This conclusion is supported by a comprehensive meta-analysis whose finding that antipsychotic polytherapy was slightly more effective than monotherapy was moderated by use of clozapine, concurrent initiation of polypharmacy at start of trial, and other treatment patterns infrequent in the US, as well as by a Chinese origin of the study (Correll, Rummel-Kluge et al. 2008). Moreover, antipsychotic polytherapy is associated with safety concerns. Randomized controlled studies (RCTs) have shown that compared to monotherapy, antipsychotic polytherapy is associated with a higher risk of nonserious side effects (e.g., extrapyramidal symptoms, sexual dysfunction, sedation) (Centorrino et al. 2004; Brooks et al. 2011). The evidence on the medium- and long-term safety of antipsychotic polytherapy comes primarily from observational studies (Correll 2008; Goff and Dixon 2011). Several but not all studies have shown that compared to monotherapy, antipsychotic polytherapy is associated with a higher risk of metabolic side effects and diabetes (Citrome, Jaffe, Levine, Allingham and Robinson, 2004; Kreyenbuhl, Valenstein, McCarthy, Ganoczy and Blow 2007; Essock et al. 2011), and cardiovascular mortality (Waddington, Youssef and Kinsella 1998; Joukamaa et al. 2006). Given that adherence is sensitive to the complexity of the treatment regimen (Chen 1991), concern exists over the adherence effects of antipsychotic polytherapy (Miller and Craig 2002; Hardeman, Harding and Narasimhan 2010), an important matter given the significance of non-adherence as a driver of poor outcomes in schizophrenia (Marcus and Olfson, 2008).</p>						
<p>The available effectiveness evidence does not support the use of antipsychotic polytherapy as specified in the proposed measure (i.e., non-clozapine antipsychotic combinations). In addition, there is direct evidence of nonserious, metabolic, and survival effects of antipsychotic polytherapy. However, its effect on antipsychotic adherence and spending on interventions of higher value have not been empirically demonstrated but rather inferred. All the RCTs that have assessed outcomes of antipsychotic polytherapy have been conducted with study populations entirely or predominantly diagnosed with schizophrenic disorders. Because no evidence exists in support of its use among individuals with other mental disorders and some evidence suggests that the practice is associated with increased side effects (Brooks et al. 2011), the specified measure also applies to other users of antipsychotic polytherapy.</p>						
<p>1c.5 Quantity of Studies in the Body of Evidence (<i>Total number of studies, not articles</i>): 34</p>						
<p>1c.6 Quality of Body of Evidence (<i>Summarize the certainty or confidence in the estimates of benefits and harms to patients across studies in the body of evidence resulting from study factors. Please address: a) study design/flaws; b)</i></p>						

directness/indirectness of the evidence to this measure (e.g., interventions, comparisons, outcomes assessed, population included in the evidence); and c) imprecision/wide confidence intervals due to few patients or events): Evidence related to the effectiveness of antipsychotic polytherapy is limited due to the narrow focus of the studies that have been published based on the review by Correll et al. (2009). Many types of individuals with schizophrenia are not included in these studies. As stated by the authors, "data [from the 19 studies reviewed] were insufficient to determine to what degree these results generalize to females, patients treated in the Western world, nonclozapine combinations, and whether antipsychotic cotreatment should be initiated concurrently in acutely exacerbated patients or whether it should be limited to sequential combinations in patients with insufficient response to antipsychotic monotherapy. Moreover, data were insufficient to determine the effect of specific combinations, long-term effects, and cost, further pointing to the need for more studies. Correll also makes the point that "insufficient data were available to evaluate the acute and even less data were available to evaluate the long-term safety of antipsychotic cotreatments. This is an important shortcoming as several cross-sectional and naturalistic studies reported an increased risk for diabetes and cardiovascular mortality associated with antipsychotic polypharmacy." The only RCT that has examined the effectiveness and safety effects of switching from antipsychotic polypharmacy to monotherapy –a 6-month open-label trial- found that antipsychotic polypharmacy was associated with weight gain and switch to monotherapy was associated with weight loss (Essock et al. 2011). However, the authors did not find differences in sexual or neurological side effects. In summary, methodological problems limit the quality of the safety evidence.

1c.7 Consistency of Results across Studies (*Summarize the consistency of the magnitude and direction of the effect*): Published studies have failed to demonstrate a benefit of antipsychotic polytherapy with the exception of combinations using clozapine which has been excluded from this measure. In addition there is some evidence to suggest that polytherapy is associated with safety concerns.

1c.8 Net Benefit (*Provide estimates of effect for benefit/outcome; identify harms addressed and estimates of effect; and net benefit - benefit over harms*):

There is no evidence supporting the use of antipsychotic polytherapy as specified in the proposed measure (Correll, Rummel-Kluge et al. 2009; Freudenreich, & Goff, 2002; Goodwin et al. 2009; Stahl, & Grady, 2004; Tranulis et al. 2008). Although the evidence regarding the safety of the practice is less developed, studies of variable methodological soundness suggest that antipsychotic polytherapy is associated with metabolic morbidity and premature cardiovascular mortality (Waddington et al. 1998; Citrome et al. 2004; Joukamaa et al. 2006; Kreyenbuhl et al. 2007; Essock et al. 2011). At a systems level, antipsychotic polytherapy may negatively impact quality of care because its high direct costs (Valuck et al. 2007; Zhu, Ascher-Svanum, Faries, Correll and Kane 2008) are likely to be offset by lower public spending on other interventions, including those with empirical support.

1c.9 Grading of Strength/Quality of the Body of Evidence. Has the body of evidence been graded? **No**

1c.10 If body of evidence graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias: **Not Applicable**

1c.11 System Used for Grading the Body of Evidence: **Other**

1c.12 If other, identify and describe the grading scale with definitions: **Not applicable**

1c.13 Grade Assigned to the Body of Evidence: **Not applicable**

1c.14 Summary of Controversy/Contradictory Evidence: **Not applicable**

1c.15 Citations for Evidence other than Guidelines(*Guidelines addressed below*):

Brooks, J. O., 3rd, et al. (2011). Safety and Tolerability Associated with Second-Generation Antipsychotic Polytherapy in Bipolar Disorder: Findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. Journal of Clinical Psychiatry, 72, 240-247.

Centorrino, F., et al. (2004). Multiple Versus Single Antipsychotic Agents for Hospitalized Psychiatric Patients: Case-Control Study of Risks Versus Benefits. American Journal of Psychiatry, 161, 700 - 706.

Chen, A. (1991). Noncompliance in Community Psychiatry: A Review of Clinical Interventions. Hospital and Community Psychiatry,

42, 282-287.

Citrome, L., Jaffe, A., Levine, J., Allingham, B., and Robinson, J. (2004). Relationship between Antipsychotic Medication Treatment and New Cases of Diabetes among Psychiatric Inpatients. *Psychiatric Services*, 55, 1006-1013.

Correll, C. U. (2008). Antipsychotic Polypharmacy, Part 2: Why Use 2 Antipsychotics When 1 Is Not Good Enough? *Journal of Clinical Psychiatry*, 69, 860-861.

Correll, C.U., Rummel-Kluge, C., Corves, C., Kane, J.M., Leucht, S. (2009). Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. *Schizophrenia Bulletin*, 35(2), 443-457

Essock, S. M., et al. (2011). Effectiveness of Switching from Antipsychotic Polypharmacy to Monotherapy. *American Journal of Psychiatry*, 168, 702-708.

Freudenreich, O, & Goff, D. C. (2002). Antipsychotic Combination Therapy in Schizophrenia. A Review of Efficacy and Risks of Current Combinations. *Acta Psychiatrica Scandinavica*, 106, 323 - 330.

Goff, D. C., and Dixon, L. (2011). Antipsychotic Polypharmacy: Are Two Ever Better Than One? *American Journal of Psychiatry*, 168, 667-669.

Goodwin, G., Fleischhacker, W., Arango, C., Baumann, P., Davidson, M., de Hert, M., et al. (2009). Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. *European Neuropsychopharmacology*, 19 (7), 520-32.

Hardeman, S. M., Harding, R. K., and Narasimhan, M. (2010). Simplifying Adherence in Schizophrenia. *Psychiatric Services*, 61, 405-408.

Joukamaa, M., et al. (2006). Schizophrenia, Neuroleptic Medication and Mortality. *British Journal of Psychiatry*, 188, 122-127.

Kreyenbuhl, J. A., Valenstein, M., McCarthy, J. F., Ganoczy, D., and Blow, F. C. (2007). Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient Characteristics and Treatment Patterns. *Psychiatric Services*, 58, 489-495.

Marcus, S. C., and Olfson, M. (2008). Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia. *Schizophrenia Bulletin*, 34, 173-180.

Miller, A. L., and Craig, C. S. (2002). Combination Antipsychotics: Pros, Cons, and Questions. *Schizophrenia Bulletin*, 28, 105-109.

Stahl, S.M. & Grady, M.M. (2004). A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy augmentation. *Current Medical Chemistry*, 11, 313-327.

Tranulis, C., Skalli, L., Lalonde, P., Nicole, L. (2008). Benefits and risks of antipsychotic polypharmacy. An evidence based review of the literature. *Drug Safety*, 31, 7-20.

Valuck, R. J., et al. (2007). How Expensive Is Antipsychotic Polypharmacy? Experience from Five US State Medicaid Programs. *Current Medical Research and Opinion*, 23, 2567-2576.

Waddington, J. L., Youssef, H. A., and Kinsella, A. (1998). Mortality in Schizophrenia. Antipsychotic Polypharmacy and Absence of Adjunctive Anticholinergics over the Course of a 10-Year Prospective Study. *British Journal of Psychiatry*, 173, 325-329.

Zhu, B., Ascher-Svanum, H., Faries, D., Correll, C., and Kane, J. (2008). Cost of Antipsychotic Polypharmacy in the Treatment of Schizophrenia. *BMC Psychiatry*, 8, 19.

1c.16 Quote verbatim, the specific guideline recommendation (Including guideline # and/or page #):

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements (Buchanan et al., 2010) suggest the evidence to support polytherapy is lacking and states on page 84, "The majority of studies of combinations of antipsychotic medications have examined the efficacy and safety of a single combination: clozapine and risperidone. These studies have failed to document sufficient efficacy and safety of this combination to support a recommendation in people with treatment-resistant schizophrenia."

1c.17 Clinical Practice Guideline Citation: Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P.R., Keller, W. (2010). The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. *Schizophrenia Bulletin*, 36(1), 71-93.

1c.18 National Guideline Clearinghouse or other URL:

<http://schizophreniabulletin.oxfordjournals.org.lp.hscl.ufl.edu/cgi/content/full/36/1/71>

1c.19 Grading of Strength of Guideline Recommendation. Has the recommendation been graded? **No**

1c.20 If guideline recommendation graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias:

1c.21 System Used for Grading the Strength of Guideline Recommendation: Other

1c.22 If other, identify and describe the grading scale with definitions: The authors of the guidelines have not issued a treatment recommendation regarding the use of antipsychotic polytherapy as studies have failed to document sufficient efficacy and safety of any combination of antipsychotic medications.

1c.23 Grade Assigned to the Recommendation: Not graded

1c.24 Rationale for Using this Guideline Over Others: The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements were selected as these were the most recent guidelines available for the treatment of patients with schizophrenia.

Based on the NQF descriptions for rating the evidence, what was the developer's assessment of the quantity, quality, and consistency of the body of evidence?

1c.25 Quantity: Moderate 1c.26 Quality: High 1c.27 Consistency: High

Was the threshold criterion, *Importance to Measure and Report*, met?

(1a & 1b must be rated moderate or high and 1c yes) Yes No

Provide rationale based on specific subcriteria:

For a new measure if the Committee votes NO, then STOP.

For a measure undergoing endorsement maintenance, if the Committee votes NO because of 1b. (no opportunity for improvement), it may be considered for continued endorsement and all criteria need to be evaluated.

2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (evaluation criteria)

Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. Testing information and results should be entered in the appropriate field. Supplemental materials may be referenced or attached in item 2.1. See [guidance on measure testing](#).

S.1 Measure Web Page (*In the future, NQF will require measure stewards to provide a URL link to a web page where current detailed specifications can be obtained*). Do you have a web page where current detailed specifications for this measure can be obtained? **No**

S.2 If yes, provide web page URL:

2a. RELIABILITY. Precise Specifications and Reliability Testing: H M L I**2a1. Precise Measure Specifications.** (*The measure specifications precise and unambiguous.*)

2a1.1 Numerator Statement (*Brief, narrative description of the measure focus or what is being measured about the target population, e.g., cases from the target population with the target process, condition, event, or outcome*):

Individuals in the denominator who are prescribed 2 or more concurrent routinely scheduled antipsychotic medications.

2a1.2 Numerator Time Window (*The time period in which the target process, condition, event, or outcome is eligible for inclusion*):

Eligible dispensings are those that occur during the entire 12-month measurement period.

2a1.3 Numerator Details (*All information required to identify and calculate the cases from the target population with the target process, condition, event, or outcome such as definitions, codes with descriptors, and/or specific data collection items/responses*):

Concurrent therapy is defined as use of one routinely scheduled oral antipsychotic medication that overlaps with the use of another routinely scheduled oral antipsychotic medication (different generic name or generic product identifier (GPI)) by at least 90 days.

2a1.4 Denominator Statement (*Brief, narrative description of the target population being measured*):

Individuals 18 years of age and older who were prescribed at least one routinely scheduled oral antipsychotic medication during the measurement period.

2a1.5 Target Population Category (*Check all the populations for which the measure is specified and tested if any*): Adult/Elderly Care

2a1.6 Denominator Time Window (*The time period in which cases are eligible for inclusion*):

12-month measurement period (or calendar year).

2a1.7 Denominator Details (*All information required to identify and calculate the target population/denominator such as definitions, codes with descriptors, and/or specific data collection items/responses*):

Denominator Inclusions: All individuals who were prescribed at least one routinely scheduled oral antipsychotic medication during the measurement period.

A routinely scheduled antipsychotic medication, as designated by the unique generic name or 10 digit GPI, is one having at least 2 consecutive dispensings of at least 25 days-supply. "Consecutive" is defined as the days' supply for the first dispensing divided by the difference in days between the first and next dispensing is = 0.8.

Oral Antipsychotics are identified by National Drug Code (Please Reference Attachment A) and include all oral formulations of the following active ingredients:

- Chlorpromazine, fluphenazine, haloperidol, loxapine, molindone, perphenazine, perphenazine-amitriptyline, pimozide, prochlorperazine, thioridazine, thiothixene, trifluoperazine, aripiprazole, asenapine, olanzapine, olanzapine-fluoxetine, iloperidone, lurasidone, paliperidone, quetiapine, risperidone, ziprasidone

2a1.8 Denominator Exclusions (*Brief narrative description of exclusions from the target population*):

- Individuals who received a dispensing for clozapine any time during the measurement period
- Individuals who died during the measurement period

2a1.9 Denominator Exclusion Details (*All information required to identify and calculate exclusions from the denominator such as definitions, codes with descriptors, and/or specific data collection items/responses*):

Clozapine is identified by National Drug Code (Please Reference Attachment A) and includes all formulations.

The death date is extracted from the beneficiary table in the CMS Claims/EDB Warehouse.

2a1.10 Stratification Details/Variables (*All information required to stratify the measure results including the stratification variables, codes with descriptors, definitions, and/or specific data collection items/responses*):

Depending on the operational use the measure results may be stratified by:

State

Plan

Physician Group

Gender

Age – Divide age group 18-64 into 3 categories: 18-24, 25-44, 45-64

Race/ethnicity**Eligibility**

The beneficiary's state of residence, birth date, death date (if any), race and gender are extracted from the Beneficiary table on the CMS Claims/EDB Warehouse. The age at the end of the measurement period is calculated using the birth date for each beneficiary and is used when stratifying the results in the different age categories. Plan and physician group attribution methodology is provided in the calculation algorithm section.

2a1.11 Risk Adjustment Type (Select type. Provide specifications for risk stratification in 2a1.10 and for statistical model in 2a1.13): **No risk adjustment or risk stratification** **2a1.12 If "Other," please describe:**

2a1.13 Statistical Risk Model and Variables (Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development should be addressed in 2b4.):

Not applicable

2a1.14-16 Detailed Risk Model Available at Web page URL (or attachment). Include coefficients, equations, codes with descriptors, definitions, and/or specific data collection items/responses. Attach documents only if they are not available on a webpage and keep attached file to 5 MB or less. NQF strongly prefers you make documents available at a Web page URL. Please supply login/password if needed:

2a1.17-18. Type of Score: Rate/proportion

2a1.19 Interpretation of Score (Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score): **Better quality = Lower score**

2a1.20 Calculation Algorithm/Measure Logic(Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.):

Denominator: Individuals who were prescribed at least one routinely scheduled oral antipsychotic medication during the measurement period (Attachment A — Table 1).

A routinely scheduled antipsychotic medication, as designated by the unique generic name or 10 digit generic product identifier (GPI), is one having at least 2 consecutive dispensings of at least 25 days supply for each dispensing. Consecutive is defined as having a medication possession ratio (MPR) of at least 0.8. The MPR is calculated as the days supply of the first dispensing divided by the difference in days between the first fill date and the next fill date.

1. Include individuals 18 or older as of December 31st of the measurement year.
2. Include individuals who were continuously enrolled in Part D, meaning they have no more than a one-month gap in enrollment during the measurement year.
3. Exclude individuals who died during the measurement year.
4. Pull all Part D claims for antipsychotics during the current measurement year.
5. Pull the generic name or GPI from the NDC file used to create the antipsychotic format into the Part D claims file from step 4.
6. Merge the antipsychotics Part D claims file with the eligibility file from step 3 to create a dataset with all Part D claims for eligible individuals.
7. Include individuals who had at least 1 routinely scheduled oral antipsychotic medication (2 consecutive dispensings of at least a 25 days supply each) during the measurement year:
 - a) Sort the dataset by individual HIC number (bene_clm_num_curr_xref), generic name or GPI, fill date (rx_service_dt), and descending days supply.

- b) De-duplicate by individual HIC number (bene_clm_num_curr_xref), generic name or GPI, and fill date (rx_service_dt), keeping the antipsychotic claim with the largest days supply if there are multiple prescribed on the same date of service.
 - c) Keep only claims for individuals that have at least one antipsychotic medication with at least two dispensings each (with at least 25 days supply each)
 - d) For each individual and generic name or GPI, calculate the MPR (as defined above) for all of the dispensings.
 - e) If the MPR = 0.8, then flag the claim as "consecutive claim" and keep the individual in the denominator
 - f) Exclude individuals who did not have at least 1 medication (generic name) with 2 consecutive 25+ days supply claims/dispensings during the measurement year.
8. Exclude individuals who received clozapine during the measurement year.

Numerator: Individuals in the denominator who are prescribed 2 or more concurrent routinely scheduled antipsychotic medications. Concurrent therapy is defined as use of one routinely scheduled oral antipsychotic medication that overlaps with the use of another (different generic name) scheduled oral antipsychotic medication by at least 90 days.

1. Keep the Part D claims for the routinely scheduled oral antipsychotic medications for the individuals identified in the denominator. Make sure the dataset is still sorted by individual HIC number (bene_clm_num_curr_xref), generic name or GPI, and fill date (rx_service_dt).
2. Exclude the individuals who only have one routinely scheduled oral antipsychotic medication during the measurement period.
3. Create a start date and end date for each period of consecutive therapy for each oral antipsychotic medication (generic name): See example table.
 - a) The start date is the fill date of the first dispensing of an antipsychotic medication.
 - b) The next dispensing is added to the period of therapy if the MPR is = 0.8 (consecutive).
 - c) This continues until the MPR is not = 0.8. If the MPR is not = 0.8 (not consecutive), then the end date of the consecutive therapy period is the fill date + days supply for the last consecutive dispensing prior to the nonconsecutive dispensing.
 - d) The start date for the next consecutive therapy period of the same antipsychotic (generic name or GPI) is the fill date of the first dispensing that occurred after the last consecutive therapy period.
 - e) Repeat Steps 3b) & 3c) to calculate the end date next consecutive therapy period.
 - f) Continue this method until the last dispensing is reached. If the end date is calculated to be after the end of the current measurement year, then the end date is the last day of the measurement period.

Each individual may have multiple consecutive therapy periods for a given oral antipsychotic (generic name or GPI).

4. For each individual, compare each consecutive period of therapy of an antipsychotic medication with the consecutive periods of therapy for each of the other antipsychotic medications to calculate overlap days.
5. Keep those individuals that had at least one occurrence of two different antipsychotic drugs that overlapped for at least 90 days during the measurement period.

Part D Plan Attribution:

The following is intended as guidance and reflects only one of many methodologies for assigning individuals to a Part D Plan.

1. Count Part D claims per individual per Part D Plan (contract number) for all individuals enrolled in Part D during the measurement year.
2. Attribute the individual to the plan with the maximum number of Part D claims. If a tie exists, attribute the individual to the plan that submitted the most recent claim.
3. Attach the Part D plan contract number to the denominator and numerator files by individual.

Physician Group Attribution:

Physician group attribution was adapted from Generating Medicare Physician Quality Performance Measurement Results (GEM) Project: Physician and Other Provider Grouping and Patient Attribution Methodologies (www.cms.gov/GEM). The following is intended as guidance and reflects only 1 of many methodologies for assigning individuals to a medical group. Please note that the physician group attribution methodology excludes patients that died even though the overall measure does not.

I. Identify Physician and Medical Groups

1. Identify all Tax Identification Numbers (TIN)/ National Provider Identification (NPI)/UPIN combinations from all Part B claims in the measurement year and the prior year. The NPI is for the performing provider is used.

If no NPI is available on the claim, check other data sources such as CMS provider tables or the National Plan and Provider Enumeration System (NPPES), for a current NPI based on the physician UPIN. Keep records with valid NPI. Valid NPIs have 10 numeric characters (no alpha characters).

Note: Due to NPI implementation, UPINs are not necessary for attribution using Part B data from 2008 and later.

2. For valid NPIs, pull credentials and specialty code(s). Credentials and specialty codes are pulled in the following order.
 - a. From the CMS provider tables
 - b. If not found in A, then pull from NPPES.
 3. Create 1 record per NPI with all credentials and all specialties. A provider may have more than 1 specialty.
 4. Attach TIN to NPI, keeping only those records with credentials indicating a physician (MD or DO), physician assistant (PA), or nurse practitioner (NP).
 5. Identify Medical group TINs: Medical group TINs are defined as TINs that had at least 50% of Part B carrier claim line items billed by the TIN during the measurement year or prior year. The provider specialty codes are listed in Table A.
 - a. Pull Part B records billed by TINs identified in #4 during the measurement year and prior year.
 - b. Identify claims that had the performing NPI (npi_prfrm) in the list of eligible physicians/TINs. Keeping those that match by TIN, performing NPI, and provider state code;
 - c. Calculate the percent of Part B claims that Match by TIN, npi_prfrm, and provider state code for each TIN, keeping those TINs with percent greater or equal to 50%;
 - d. Delete invalid TINs. Examples of invalid TINs are defined as having the same value for all 9 digits or values of 012345678 , 012345678, 123456789, 987654321, 87654321
 6. Identify TINs that are not solo practices
 - a. Pull Part B records billed by physicians identified in #4 for the measurement year and/or prior year. If the performing NPI is not on the claim, match to obtain NPI from the list created in #4 by UPIN
 - b. Count unique NPIs per TIN;
 - c. Keep only those TINs 2 or more providers.
 - d. Delete invalid TINs. Examples of invalid TINs are defined as having the same value for all 9 digits or values of 012345678 , 012345678, 123456789, 987654321, 87654321
 7. Create final group of TINs from #5 and #6 (TINs that are medical group and are not solo practices).
 8. Create file of TIN and NPIs associated with those TINs. These are now referred to as the medical group TIN.
- II. Identify Individual Sample and Claims
9. Create Individual Sample
 - a. Pull individuals with 11+ months of Pt A, B, & D during the measurement year
 - b. Verify the individual did not have any months with Medicare as secondary payor. Remove individuals with BENE_PRMRY_PYR_CD not in
 - A=working aged beneficiary/spouse with EGHP
 - B=ESRD in the 18 month coordination period with an employer group health plan
 - G= working disabled for any month of the year.
 - c. Verify the individual resides in the US, Puerto Rico, Virgin Islands or Washington D.C.
 - d. Exclude individuals that enter the Medicare Hospice at any point during the measurement year.
 - e. Exclude individuals that died during the measurement year
 10. For individuals identified in #9, pull office visit claims that occur during the measurement year and in the 6 months prior to the measurement year.
 - a. Office visit claims have CPT codes of 99201-99205, 99211-99215 and 99241-99245.
 - b. Exclude claims with no Physician_upin and no npi_prfrm

11. Attach medical group TIN to claims by NPI or UPIN if no performing NPI is available.

III. Patient Attribution:

12. Pull all Part B office claims from #11 with specialties indicating primary care or psychiatry (Table A). Attribute each individual to at most 1 medical group TIN for each measure.

a. Evaluate specialty on claim (HSE_B_HCFA_PRVDR_SPCLTY_CD) first. If specialty on claim does not match any of the measure-specific specialties, then check additional specialty fields.

b. If the provider specialty indicates nurse practitioners or physician assistants ('50' '97'), then check additional specialty codes

13. For each individual, count claims per medical group TIN. Keep only individuals with 2 or more E&M claims.

14. Attribute individual to the medical group TIN with the most claims. If a tie occurs between medical group TINs, attribute the TIN with most recent claim.

15. Attach the medical group TIN to the denominator and numerator files by individual.

2a1.21-23 Calculation Algorithm/Measure Logic Diagram URL or attachment:

Attachment

Measure QP4 Attachment C.doc

2a1.24 Sampling (Survey) Methodology. If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):

Not Applicable

2a1.25 Data Source (*Check all the sources for which the measure is specified and tested*). If other, please describe:

Administrative claims, Electronic Clinical Data : Pharmacy

2a1.26 Data Source/Data Collection Instrument (*Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.*): For measure calculation, the following Medicare files were required:

- Denominator tables
- Prescription drug benefit (Part D) coverage tables
- Beneficiary file
- Prescription drug benefit (Part D) claims

For physician group attribution, the following were required:

- Non-institutional claims (Part B)- physician carrier/non-DME
- Denominator tables to determine beneficiary enrollment
- Beneficiary file or coverage table to determine hospice benefit and Medicare as secondary payor status
- CMS physician and physician specialty tables
- National Plan & Provider Enumeration System (NPPES) database

2a1.27-29 Data Source/data Collection Instrument Reference Web Page URL or Attachment: [URL](http://www.resdac.org/ddvh/index.asp)

<http://www.resdac.org/ddvh/index.asp>

2a1.30-32 Data Dictionary/Code Table Web Page URL or Attachment:

Attachment

Measure QP4 Attachment A.doc

2a1.33 Level of Analysis (*Check the levels of analysis for which the measure is specified and tested*): Clinician : Group/Practice, Health Plan, Population : State

2a1.34-35 Care Setting (*Check all the settings for which the measure is specified and tested*): Ambulatory Care : Clinician Office

2a2. Reliability Testing. (*Reliability testing was conducted with appropriate method, scope, and adequate demonstration of reliability.*)

2a2.1 Data/Sample (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included:*)

A 100% sample of Medicare Parts A, B, and D for 2007 and 2008 from eight states (AZ, DE, FL, IA, IN, MS, RI, and WA) was used. The data include 4,789,034 beneficiaries, 9,406 physician groups, and 656 Part D plans.

2a2.2 Analytic Method (*Describe method of reliability testing & rationale:*)

To ensure measure specifications were completely explicit and unambiguous, an iterative process was used between independent programmers to refine measure specifications until complete agreement was achieved (See Attachment B: Table 1).

In order to assess measure precision in the context of the observed variability across measurement units (for plans and physician groups), we utilized the approach proposed by Adams et al in their work on the reliability for provider profiling for NCQA.1 The following is quoted from their tutorial:

Reliability is a key metric of the suitability of a measure for [provider] profiling because it describes how well one can confidently distinguish the performance of one physician from another. Conceptually, it is the ratio of signal to noise. The signal in this case is the proportion of the variability in measured performance that can be explained by real differences in performance. There are three main drivers of reliability: sample size, differences between physicians, and measurement error. At the physician level, sample size can be increased by increasing the number of patients in the physician's data as well as increasing the number of measures per patient.

The signal to noise ratio is calculated as a function of the variance between physician groups (signal) and the variance within a physician group (noise) (See Attachment B: Formula 1)

Reliability was estimated using a beta-binomial model. This approach has 2 basic assumptions:

1) Each physician has a true pass rate, p , which varies from physician to physician, and 2) the physician's score is a binomial random variable conditional on the physician's true value, which comes from the beta distribution. Thus, the variance between physician groups is defined as (See Attachment B Formula 2)

The physician-specific error is calculated using binomial variance for where p is the provider- specific probability of passing (See Attachment B: Formula 3).

The right hand of the formula shows that the estimator is a weighted average of the physician sample mean and the average physician mean (mean of the Beta distribution), which shrinks to the average physician mean.

Reliability scores vary from 0.0 to 1.0. A score of zero implies that all variation is attributed to measurement error (noise or the individual physician group variance), whereas a reliability of 1.0 implies that variation is caused by a real difference in performance (across physician groups). In a simulation Adams et al showed that differences between physicians started to be seen at reliability of 0.7 and significant differences could be seen at reliability 0.9. Generally, a minimum reliability score of 0.7 is used to indicate sufficient signal strength to discriminate performance between physicians.

1. Adams JL. The Reliability of Provider Profiling: A Tutorial. TR-653-NCQA, 2009.

2a2.3 Testing Results (*Reliability statistics, assessment of adequacy in the context of norms for the test conducted:*)

Plans

Requiring a minimum number of 30 patients per plan resulted in 63.9% of plans with a reliability score >0.7 . Given the distribution of reliability scores in the sample, a cut off of a denominator size of 145 would likely result in a plan sample where the majority ($>90\%$) have reliable scores. (See Attachment B: Table 1b)

The distribution of reliability scores across all Part D plans with at least 30 patients attributed is shown in Attachment B: Figure 1a.

Physician Groups

Requiring a minimum number of 30 patients per physician group resulted in 14.5% of groups with a reliability score >0.7. Given the distribution of scores in the sample, a cut off of a denominator size of 137 would likely result in a physician group sample where the majority (>90%) have reliable scores (See Attachment B: Table 1c)

The distribution of reliability scores across all physician groups with at least 30 patients attributed is shown in Attachment B: Figure 1b.

Reliability Summary

Requiring a standard minimum denominator size of at least 30 patients per plan and physician group resulted in a large proportion of plans with good reliability scores, but only a small proportion of physician groups.

2b. VALIDITY. Validity, including all Threats to Validity: H M L I**2b1.1 Describe how the measure specifications (measure focus, target population, and exclusions) are consistent with the evidence cited in support of the measure focus (criterion 1c) and identify any differences from the evidence:**

The measure focus is consistent with the evidence cited in that the studies show effectiveness data are lacking for polytherapy with oral antipsychotics across a wide range of indications and populations. Furthermore, there is some evidence to suggest that the polytherapy is associated with adverse events. In addition, the measure excludes individuals receiving clozapine because there are data to suggest that a polytherapy regimen including clozapine may be effective.

2b2. Validity Testing. (*Validity testing was conducted with appropriate method, scope, and adequate demonstration of validity.*)**2b2.1 Data/Sample** (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included:*)

A 100% sample of Medicare Parts A, B, and D for 2007 and 2008 from eight states (AZ, DE, FL, IA, IN, MS, RI, and WA) was used. The data include 4,789,034 beneficiaries, 9,406 physician groups, and 656 Part D plans.

2b2.2 Analytic Method (*Describe method of validity testing and rationale; if face validity, describe systematic assessment:*)**Face Validity**

FMQAI's Technical Expert Panel (TEP), comprising of internal medicine physicians and pharmacists evaluated the face validity of the measure and measure scores. The following 12 TEP members evaluated the face validity of the measure and measure scores:

1. Jill S. Borchert, Pharm.D., BCPS, Professor, Pharmacy Practice & PGY1 Residency Program Director, Midwestern University, Chicago College of Pharmacy
2. Anne Burns, RPh, Vice President, Professional Affairs, American Pharmacists Association
3. Jannet Carmichael, Pharm.D., FCCP, FAPhA, BCPS, VISN 21 Pharmacy Executive, VA Sierra Pacific Network
4. Marshall H. Chin, MD, MPH, Professor of Medicine, University of Chicago
5. Jay A. Gold, MD, JD, MPH, Senior Vice President and Medicare Chief Medical Officer, MetaStar, Inc.
6. David Nau, Ph.D., R.Ph., CPHQ, Senior Director of Research & Performance Measurement, PQA, Inc.
7. N. Lee Rucker, M.S.P.H., Strategic Policy Senior Advisor, AARP - Public Policy Institute
8. Marissa Schlaifer, MS, RPh, Director of Pharmacy Affairs Academy of Managed Care Pharmacy
9. Brad Tice, Pharm.D., Chief Clinical Officer, PharmMD Solutions, LLC
10. Jennifer K. Thomas, Pharm.D., Manager, Pharmacy Services, Delmarva Foundation for Medical Care / Delmarva Foundation of the District of Columbia
11. Darren Triller, Pharm.D., Director, Pharmacy Services, IPRO
12. Neil Wenger, MD, Professor of Medicine, UCLA Department of Medicine, Division of General Internal Medicine and Health Services Research

The evaluation of face validity was conducted through an online review process using a web-based questionnaire (developed using SurveyMonkey).

Face validity of the measure score as an indicator of quality was systematically assessed as follows:

1. After the measure was fully specified and tested, the expert panel (membership) was asked to rate, based on a 5-point Likert scale, their level of agreement with the following statement:

"The measure appears to measure what is intended."

2. The 5-point Likert scale was defined as follows: 1=Strongly Disagree; 2= Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

Threats to Validity

An empirical assessment of identified threats to validity was conducted as follows:

- A. Threat of Misclassification or Inability to Distinguish Comparative Quality from Measure Scores Related to Statistical Methods

The observed sample sizes of members of each comparison unit were tested empirically to determine whether there was sufficient power to detect statistically significant differences between members (e.g., between plans or between physician groups). As such, this approach follows the analysis presented under the reliability testing but utilizes all plans or physician groups (regardless of reliability score threshold). All members were divided into quintiles according to their measure score. Within each quintile, the member with a denominator closest in size to the median denominator of the quintile and the member with the measure score closest to the median measure score of that quintile were identified. Comparison of members based on their median denominator size was made because a relationship between denominator size and quality cannot be excluded a priori. In addition, a "standardized" member of each quintile was simulated by using the median denominator size across all quintiles. Binomial (exact) 95% confidence intervals for each of the 10 selected plans or physician groups (i.e., two plans or physician groups per quintile) were calculated around the point estimates. Overlapping confidence intervals indicate insufficient statistical power to detect statistically significant differences.

The distribution of denominator sizes across members of each quintile in a given comparison was also calculated to illustrate variation of sample size and the inherent consequences for random error. These results are shown in Attachment B: Tables 2 and 3.

- B. Threat of Bias from Missing Data

We have identified two potential scenarios where measure results could be biased by missing data:

1. Missing days' supply within the prescription drug event data
2. Missing drug claims due to individuals using alternative payment sources for prescription drugs, e.g., VA prescription benefits or commercial discount prescription programs, such as the Walmart \$4 generic program

Threat of bias due to missing days' supply applies to this measure because it uses this data element to define the numerator and denominator. . The threat of potential bias from cash prescriptions is also applicable to this measure, because some of the drugs in the measure were available on the Wal-Mart \$4 commercial discount programs in 2008.

Wal-Mart. (2008). \$4 Prescription Program. Retrieved January 15, 2011, from <http://i.walmart.com/iif/hmp/fusion/genericdruglist.pdf>

Attachment B: Table 4 summarizes findings related to missing data analyses. Attachment B: Table 5 summarizes findings related to cash prescriptions.

2b2.3 Testing Results (Statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment):

Results

Face Validity

Ninety-two percent of TEP members who responded to the survey either strongly agreed or agreed that the measure has face validity.

The scores obtained from the systematic assessment of face validity revealed the following results:

Strongly Agree = 25.0% (3/12)

Agree = 66.7% (8/12)

Neutral = 8.3% (1/12)
 Disagree = 0.0% (0/12)
 Strongly Disagree = 0.0% (0/12)

Threats to Validity

A. Threat of Misclassification or Inability to Distinguish Comparative Quality from Measure Scores Related to Statistical Methods

A total of 128 plans with at least 30 beneficiaries could be distributed across the measure score quintiles. Plans selected showed pronounced variation in sample size with a trend of the largest plans in the lowest performing quintiles (4 and 5). Comparison of individual plans (selected based on the median measure score within each quintile) showed sufficient discriminatory ability, based on lack of overlap between the confidence intervals of the lowest and highest performing quintiles, but this was not the case for the plans selected based on the median denominator size. Similarly, comparison of standardized plans (with confidence intervals calculated based on median denominator size of the entire sample) showed sufficient discriminatory ability between members of the highest and lowest quintiles. Of note, the sample sizes for plans varied dramatically within each quintile and will result in distinctly different power if two members are compared (See Attachment B: Table 4)

Assuming a median measure rate of 5.1% and a median denominator of 198 beneficiaries, the smallest difference in measure rates that can be detected at the plan level with a power of 80% and $\alpha=0.05$ is 5.7%.

A total of 365 physician groups with at least 30 beneficiaries could be distributed across the measure score quintiles. Physician groups showed variation in sample size with no particular pattern with respect to measure scores. We noted pronounced variation in measure rates across physician groups ranging from 0.0 to 41.5%. Comparison of individual groups (selected based on median denominator size) showed discriminatory ability between the highest and lowest quintile. Comparison of standardized physician groups (calculated based on median denominator size) showed limited discriminatory ability based on substantial overlap between the confidence intervals across all quintiles. (See Attachment B: Table 5)

Of note, given the small sample sizes for physician groups, variation in measure scores will need to be pronounced to allow statistically significant comparisons.

Assuming a median measure rate of 9.6% and a median denominator of 55 beneficiaries, the smallest difference that can be detected at the physician group level with a power of 80% and $\alpha=0.05$ is 12.5%.

B. Threat of Bias from Missing Data

Attachment B: Table 6 summarizes findings related to missing data analyses. Nearly all claims had complete information for days' supply, and no impact on the accuracy of the measure was demonstrated.

In Attachment B: Table 5, we present the results of a limited sensitivity analysis using the two-state sample (FL and RI) to estimate the potential impact of missing data from the Wal-Mart \$4 discount program. Using the Wal-Mart \$4 formulary [Wal-Mart. (2008). \$4 Prescription Program. Retrieved January 15, 2011, from <http://i.walmart.com/iif/hmp/fusion/genericdruglist.pdf>], we created a National Drug Code (NDC) list of the products included on the formulary. We then determined the percentage of beneficiaries who had no Part D claims for any drug listed in the formulary. For these beneficiaries, we determined which beneficiaries who had a claim for an antipsychotic on the Wal-Mart list also had no claims for any other drugs on the formulary. Finally, in the last step, we simulated the effect on measure rates if each of these beneficiaries' antipsychotic drug use extended from the last consecutive claim to the end of the measurement period by assuming they continued to receive the drug from the commercial discount program. The results when compared to the original measure results for the two-state sample indicated a negligible impact on measure rates.

The findings suggest that very little impact on measure rates would be expected from utilization of the Wal-Mart program, particularly at the state/population/level. This analysis could be confirmed with external validation; however, such validation was

beyond the scope of the current project.

Additional limitations include prescriptions filled with other benefits (e.g., VA) could not be assessed, and thus, the extent to which this measure might underestimate antipsychotic polytherapy is unknown. Likewise, if all antipsychotic medications were obtained through the Wal-Mart program, the denominator could miss 7.8% or more patients who may or may not have similar polytherapy rates as those included in the analysis at hand.

Validity Summary

In summary, there was strong agreement among the members of the Technical Expert Panel (TEP) that the measure reflected quality of care. Furthermore, threats to validity were not identified with the exception of potential misclassification of comparative quality at the physician group level. This concern will be further explored with data in a CMS quality reporting program.

POTENTIAL THREATS TO VALIDITY. (*All potential threats to validity were appropriately tested with adequate results.*)

2b3. Measure Exclusions. (*Exclusions were supported by the clinical evidence in 1c or appropriately tested with results demonstrating the need to specify them.*)

2b3.1 Data/Sample for analysis of exclusions (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included:*)

A 100% sample of Medicare Parts A, B, and D for 2007 and 2008 from eight states (AZ, DE, FL, IA, IN, MS, RI, and WA) was used. The data include 4,789,034 beneficiaries, 9,406 physician groups, and 656 Part D plans.

2b3.2 Analytic Method (*Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference:*)

Individuals who received a dispensing for clozapine any time during the measurement period and individuals who died during the measurement period were excluded from the denominator.

Patients receiving clozapine are excluded from the measure, since polytherapy with clozapine has shown some evidence of benefit (Correll et al., 2009).

We present descriptive results including measure scores with and without exclusion of patients with claims that would indicate use of clozapine.

2b3.3 Results (*Provide statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses:*)

As reflected in Attachment B Table 6, less than 2% of all patients received clozapine during the measurement period. Measure rates were quite similar when those beneficiaries were included or excluded. However, because the evidence suggests possible benefit of polytherapy for those beneficiaries using clozapine, excluding these individuals will increase measure validity.

2b4. Risk Adjustment Strategy. (*For outcome measures, adjustment for differences in case mix (severity) across measured entities was appropriately tested with adequate results.*)

2b4.1 Data/Sample (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included:*)

Not applicable

2b4.2 Analytic Method (*Describe methods and rationale for development and testing of risk model or risk stratification including selection of factors/variables:*)

Not applicable

2b4.3 Testing Results (*Statistical risk model:* Provide quantitative assessment of relative contribution of model risk factors; risk model performance metrics including cross-validation discrimination and calibration statistics, calibration curve and risk decile plot, and assessment of adequacy in the context of norms for risk models. *Risk stratification:* Provide quantitative assessment of relationship of risk factors to the outcome and differences in outcomes among the strata):

Not applicable

2b4.4 If outcome or resource use measure is not risk adjusted, provide rationale and analyses to justify lack of

adjustment: Not applicable

2b5. Identification of Meaningful Differences in Performance. (*The performance measure scores were appropriately analyzed and discriminated meaningful differences in quality.*)

2b5.1 Data/Sample (*Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):

A 100% sample of Medicare Parts A, B, and D for 2007 and 2008 from eight states (AZ, DE, FL, IA, IN, MS, RI, and WA) was used. The data include 4,789,034 beneficiaries, 9,406 physician groups, and 656 Part D plans.

2b5.2 Analytic Method (*Describe methods and rationale to identify statistically significant and practically/meaningfully differences in performance*):

Statistically significant differences in performance are addressed in the validity section. To assess meaningful differences in performance, the distribution of measure scores was calculated for states (Attachment B: Table 7), plans (Attachment B: Table 8) and physician groups (Attachment B: Table 9).

2b5.3 Results (*Provide measure performance results/scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance*):

Attachment B: Table 7 shows the measure results for the eight states included in the field testing. Measure rates ranged from 6.4% to 10.8%. Attachment B: Table 7b shows the measure distribution for the eight states. Measure rates ranged from 6.4% at the 10th percentile to 10.8% at the 90th percentile.

Attachment B: Table 8 shows the plan performance. Less than one-third of all plans included more than 30 patients eligible for the measure in the measurement year. However, since the measure included both Medicare Advantage Prescription Drug Plans (MA-PDs) and Prescription Drug Plans (PDPs), the number of plans eligible for comparisons was 432, retaining a sizeable number of plans and beneficiaries for analysis and benchmarking. Measure rates for all plans ranged from 2.1% (10th percentile) to 10.6% (90th percentile) with a mean score of 5.9%. Distribution of scores indicated higher rates for PDPs than for MA-PDs.

Attachment B: Table 9 shows the physician group performance. The number of physician groups with at least 30 individuals was limited to 365 practice groups from the eight-state sample, and three of the eight states had less than 30 groups with 30 individuals attributed. For all groups, rates ranged from 3.7% (10th percentile) to 17.5% (90th percentile) with a mean of 10.3%.

2b6. Comparability of Multiple Data Sources/Methods. (*If specified for more than one data source, the various approaches result in comparable scores.*)

2b6.1 Data/Sample (*Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):

Not Applicable

2b6.2 Analytic Method (*Describe methods and rationale for testing comparability of scores produced by the different data sources specified in the measure*):

Not Applicable

2b6.3 Testing Results (*Provide statistical results, e.g., correlation statistics, comparison of rankings; assessment of adequacy in the context of norms for the test conducted*):

Not Applicable

2c. Disparities in Care: H M L I NA (*If applicable, the measure specifications allow identification of disparities.*)

2c.1 If measure is stratified for disparities, provide stratified results (*Scores by stratified categories/cohorts*): Rates by age and race/ethnicity are shown in Attachment B: Table 10 for the entire eight-state sample. The rate of polytherapy decreased with age after age 25. Hispanics had the lowest rate of polytherapy up until age 75; African Americans had the highest rates of polytherapy in 5 of the 6 age groups.

Rates are shown for beneficiaries stratified by age and dual-eligible status in Attachment B: Table 11. In all age groups, dual-eligible beneficiaries had higher rates of polytherapy than those who are not dual-eligible.

Rates by gender and age group are shown in Attachment B: Table 12 for the entire eight-state sample. Overall, males had a polytherapy rate 4.5% higher than females. The females' polytherapy rate decreased with increasing age. For males, the age group of 25-44 years had the highest polytherapy rate at 15.6% and then the rate decreased in the older age groups.

2c.2 If disparities have been reported/identified (e.g., in 1b), but measure is not specified to detect disparities, please explain:

Not applicable

2.1-2.3 Supplemental Testing Methodology Information:

Attachment

Measure QP4 Attachment B.pdf

Steering Committee: Overall, was the criterion, *Scientific Acceptability of Measure Properties*, met?

(*Reliability and Validity must be rated moderate or high*) Yes No

Provide rationale based on specific subcriteria:

If the Committee votes No, STOP

3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)

C.1 Intended Purpose/ Use (Check all the purposes and/or uses for which the measure is intended): Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

3.1 Current Use (Check all that apply; for any that are checked, provide the specific program information in the following questions): Not in use

3a. Usefulness for Public Reporting: H M L I

(The measure is meaningful, understandable and useful for public reporting.)

3a.1. Use in Public Reporting - disclosure of performance results to the public at large (If used in a public reporting program, provide name of program(s), locations, Web page URL(s)). If not publicly reported in a national or community program, state the reason AND plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement: **[For Maintenance – If not publicly reported, describe progress made toward achieving disclosure of performance results to the public at large and expected date for public reporting; provide rationale why continued endorsement should be considered.]**

New measure not currently in use, however, measures are planned for implementation in various CMS reporting programs within the next three years.

3a.2. Provide a rationale for why the measure performance results are meaningful, understandable, and useful for public reporting. If usefulness was demonstrated (e.g., focus group, cognitive testing), describe the data, method, and results: Ratings from 12 out of 14 members of the Technical Expert Panel (TEP). The TEP members were asked to assess the interpretability of the measures and measure scores through an online review process. Eighty-three percent of TEP members who responded to the survey strongly agreed or agreed that the measure scores were interpretable.

3.2 Use for other Accountability Functions (payment, certification, accreditation). If used in a public accountability program, provide name of program(s), locations, Web page URL(s): Not applicable

3b. Usefulness for Quality Improvement: H M L I

(The measure is meaningful, understandable and useful for quality improvement.)

3b.1. Use in QI. If used in quality improvement program, provide name of program(s), locations, Web page URL(s):

[For Maintenance – If not used for QI, indicate the reasons and describe progress toward using performance results for]

improvement].

New measure not currently in use.

3b.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for quality improvement. If usefulness was demonstrated (e.g., QI initiative), describe the data, method and results:

Ratings from 12 out of 14 members of the Technical Expert Panel (TEP). The TEP members were asked to assess the interpretability of the measures and measure scores through an online review process. Eighty-three percent of TEP members who responded to the survey strongly agreed or agreed that the measure scores were interpretable.

Overall, to what extent was the criterion, *Usability*, met? H M L I

Provide rationale based on specific subcriteria:

4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)

4a. Data Generated as a Byproduct of Care Processes: H M L I

4a.1-2 How are the data elements needed to compute measure scores generated? (Check all that apply).

Data used in the measure are:

Coded by someone other than person obtaining original information (e.g., DRG, ICD-9 codes on claims)

4b. Electronic Sources: H M L I

4b.1 Are the data elements needed for the measure as specified available electronically (Elements that are needed to compute measure scores are in defined, computer-readable fields): ALL data elements in electronic claims

4b.2 If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources:

4c. Susceptibility to Inaccuracies, Errors, or Unintended Consequences: H M L I

4c.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to prevent, minimize, or detect. If audited, provide results:

These data are used for payment of medical services, so they are routinely audited by Medicare.

4d. Data Collection Strategy/Implementation: H M L I

A.2 Please check if either of the following apply (regarding proprietary measures): Proprietary measure

4d.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues (e.g., fees for use of proprietary measures):

Testing demonstrated that the measure was feasible to specify and calculate using CMS administrative claims data. Data sources needed to implement the measure are readily available, accessible, and timely. No threats to the validity of this measure were identified using a limited analysis designed to address missing data (Reference Validity Testing Section).

Overall, to what extent was the criterion, *Feasibility*, met? H M L I

Provide rationale based on specific subcriteria:

OVERALL SUITABILITY FOR ENDORSEMENT

Does the measure meet all the NQF criteria for endorsement? Yes No

Rationale:

If the Committee votes No, STOP.

If the Committee votes Yes, the final recommendation is contingent on comparison to related and competing measures.

5. COMPARISON TO RELATED AND COMPETING MEASURES

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are compared to address harmonization and/or selection of the best measure before a final recommendation is made.

5.1 If there are related measures (*either same measure focus or target population*) or competing measures (*both the same measure focus and same target population*), list the NQF # and title of all related and/or competing measures:

0552 : HBIPS-4: Patients discharged on multiple antipsychotic medications.

0560 : HBIPS-5 Patients discharged on multiple antipsychotic medications with appropriate justification

5a. Harmonization

5a.1 If this measure has EITHER the same measure focus OR the same target population as NQF-endorsed measure(s):
Are the measure specifications completely harmonized? **No**

5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden:

The Joint Commission measures are based on administrative clinical data and medical records whereas the proposed measure is based on administrative claims data. Measure specifications are harmonized with the Joint Commission measures to the extent possible, with modifications as necessary for use in the outpatient setting and for calculation using claims data sources solely. Other key differences include for the proposed measure: limiting medications to oral formulations due to limitations regarding the validity of the days supply variable for the injectable formulations and excluding clozapine which is the only combination therapy for which evidence indicating effectiveness exists. Furthermore, the Joint Commission measures are limited to psychiatric patients, whereas, the CMS measure is intended for all patients receiving oral antipsychotics, regardless of indication. The proposed measure, because it is based on administrative claims data, has a lower data collection burden.

5b. Competing Measure(s)

5b.1 If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s):

Describe why this measure is superior to competing measures (e.g., a more valid or efficient way to measure quality); OR provide a rationale for the additive value of endorsing an additional measure. (Provide analyses when possible):

The endorsed measures are limited to psychiatric patients discharged from an inpatient setting. The proposed measure would be applicable to all patients on antipsychotic medications in an ambulatory care setting and would complement the existing Joint Commission measures.

CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner): Centers for Medicare & Medicaid Services, 7500 Security Blvd., Mail Stop: S3-02-01, Baltimore, Maryland, 21244

Co.2 Point of Contact: Noni, Bodkin, PhD, RN, Noni.Bodkin@cms.hhs.gov, 410-786-7837-

Co.3 Measure Developer if different from Measure Steward: FMQAI, 5201 W. Kennedy Blvd., Suite 900, Tampa, Florida, 33609

Co.4 Point of Contact: Kyle, Campbell, Pharm.D., kcAMPbell@flqio.sdps.org, 813-865-3199-

Co.5 Submitter: Kyle, Campbell, Pharm.D., kcAMPbell@flqio.sdps.org, 813-865-3199-, FMQAI

Co.6 Additional organizations that sponsored/participated in measure development:

RAND Corporation: Soeren Mattke, MD, DSc, Senior Scientist and Elizabeth Sloss, PhD.

University of Florida College of Pharmacy: Almut Winterstein, PhD, Associate Professor, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy.

Health Services Advisory Group: Ryan Fair

Co.7 Public Contact: Kyle, Campbell, Pharm.D., kcAMPbell@flqio.sdps.org, 813-865-3199-, FMQAI

ADDITIONAL INFORMATION

Workgroup/Expert Panel involved in measure development

Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.

Endorsed by Quality Partners of Rhode Island's and FMQAI's Technical Expert Panels (TEP). Both TEPs were charged with evaluating the proposed measure regarding the four primary measure evaluation criteria used in the NQF consensus endorsement process (importance, scientific acceptability, feasibility, and usability). The TEPs discussed the strengths and weaknesses of the proposed measures and made recommendations regarding measure specifications, inclusion and exclusion criteria, and appropriate risk adjustment as applicable.

QPRI TEP:

1. Daniel E. Buffington, PharmD, MBA, President and CEO / Medical Director, Clinical Pharmacology Services, Inc.
2. Anne Burns, R.Ph., Vice President for Professional Affairs, American Pharmacists Association
3. Julie Kuhle, R.Ph., Pharmacy Manager, Iowa Foundation for Medical Care - QIO
4. David P. Nau, PhD, RPh, CPHQ, Manager, Research Strategies, Competitive Health Analytics, Humana Pharmacy Solutions
5. Gary Puckrein, PhD, President and Chief Executive Officer, National Minority Quality Forum
6. Marissa Schlaifer, R.Ph., M.S., Pharmacy Affairs Director Academy of Managed Care Pharmacy
7. Linda Simoni-Wastila, BS Pharm, PhD, Associate Professor, University of Maryland Baltimore, School of Pharmacy Department of Pharmaceutical Health Services Research
8. Molly Skinner, PharmD, Executive Resident, National Alliance of State Pharmacy Associations
9. Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, Founding Executive Director, TEP Chair, Health Policy Institute - Geriatric Health Program, University of the Sciences in Philadelphia
10. Kenneth H. Summers, PhD., Director of Research and Practice Improvement, PQA, Inc.
11. Jennifer Tjia, MD, MSCE, Assistant Professor of Geriatric Medicine, University of Massachusetts Medical School
12. Darren Triller, PharmD, Pharmacist, Quality Improvement IPRO (QIO)
13. Jennifer Van Meter, PharmD, CGP, Director of Clinical Medical Policy, Pharmaceutical Research and Manufacturers of America
14. F. Randy Vogenberg, R.Ph., Ph.D., Co-Founder and Chief Strategic Officer, Senior Scholar, Department of Health Policy, Jefferson Medical College, EPS, LLC
15. Ken Whittemore, Jr., R.Ph., MBA, Senior Vice President Clinical Practice Integration, SureScripts-RxHub, LLC.

FMQAI TEP:

1. Douglas Bell, MD, Associate Professor in Residence, UCLA Department of Medicine, Division of General Internal Medicine and Health Services Research
2. Jill S. Borchert, Pharm.D., BCPS, Professor, Pharmacy Practice & PGY1 Residency Program Director, Midwestern University, Chicago College of Pharmacy
3. Anne Burns, RPh, Vice President, Professional Affairs, American Pharmacists Association
4. Jannet Carmichael, Pharm.D., FCCP, FAPhA, BCPS, VISN 21 Pharmacy Executive, VA Sierra Pacific Network
5. Marshall H. Chin, MD, MPH, Professor of Medicine, University of Chicago
6. Edward Eisenberg, MD, Vice President and Chief Medical Officer, Medicare, Medco Health Solutions
7. Jay A. Gold, MD, JD, MPH, Senior Vice President and Medicare Chief Medical Officer, MetaStar, Inc.
8. David Nau, Ph.D., R.Ph., CPHQ, Senior Director of Research & Performance Measurement, PQA, Inc.
9. N. Lee Rucker, M.S.P.H., Strategic Policy Senior Advisor, AARP - Public Policy Institute
10. Marissa Schlaifer, MS, RPh, Director of Pharmacy Affairs Academy of Managed Care Pharmacy
11. Brad Tice, Pharm.D., Chief Clinical Officer, PharmMD Solutions, LLC
12. Jennifer K. Thomas, Pharm.D., Manager, Pharmacy Services, Delmarva Foundation for Medical Care / Delmarva Foundation of the District of Columbia
13. Darren Triller, Pharm.D., Director, Pharmacy Services, IPRO
14. Neil Wenger, MD, Professor of Medicine, UCLA Department of Medicine, Division of General Internal Medicine and Health Services Research

Ad.2 If adapted, provide title of original measure, NQF # if endorsed, and measure steward. Briefly describe the reasons for

adapting the original measure and any work with the original measure steward:

Measure Developer/Steward Updates and Ongoing Maintenance

Ad.3 Year the measure was first released: 2010

Ad.4 Month and Year of most recent revision: 07, 2011

Ad.5 What is your frequency for review/update of this measure? Annual

Ad.6 When is the next scheduled review/update for this measure? 11, 2011

Ad.7 Copyright statement: Not applicable, the measure is in the public domain.

Ad.8 Disclaimers:

Ad.9 Additional Information/Comments:

Date of Submission (MM/DD/YY): 09/14/2011

Attachment A – Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Table 1. Specified Oral Antipsychotic Medications, Listed by Generic/Ingredient Name*:

Typical Antipsychotics	Atypical Antipsychotics
<ul style="list-style-type: none">• chlorpromazine• fluphenazine• haloperidol• loxapine• molindone• perphenazine• perphenazine-amitriptyline• pimozide• prochlorperazine• thioridazine• thiothixene• trifluoperazine	<ul style="list-style-type: none">• aripiprazole• asenapine• olanzapine• olanzapine-fluoxetine• iloperidone• lurasidone• paliperidone• quetiapine• risperidone• ziprasidone

* Active ingredients listed are limited to oral formulations only. Obsolete drug products are excluded from National Drug Codes (NDCs) with an inactive date more than 3 years prior to the beginning of the measurement period or look back period if applicable. Note clozapine is excluded from the measure.

ndc_code	drug_id	generic_product_name	Brand_Name	Route
16590032330	59250015000305	Aripiprazole Tab 2 MG	ABILIFY	OR
16590057330	59250015000340	Aripiprazole Tab 20 MG	ABILIFY	OR
16590074530	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
16590074560	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
16590090430	59250015000350	Aripiprazole Tab 30 MG	ABILIFY	OR
21695000215	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
21695000230	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
21695000315	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
21695000330	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
21695000345	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
21695000415	59250015000330	Aripiprazole Tab 15 MG	ABILIFY	OR
21695000530	59250015000340	Aripiprazole Tab 20 MG	ABILIFY	OR
35356017130	59250015000350	Aripiprazole Tab 30 MG	ABILIFY	OR
35356056830	59250015000305	Aripiprazole Tab 2 MG	ABILIFY	OR
49848001930	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
49848002030	59250015000340	Aripiprazole Tab 20 MG	ABILIFY	OR
49848002130	59250015000350	Aripiprazole Tab 30 MG	ABILIFY	OR
49999059830	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
49999081630	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
49999081690	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
49999081730	59250015000330	Aripiprazole Tab 15 MG	ABILIFY	OR
49999081830	59250015000340	Aripiprazole Tab 20 MG	ABILIFY	OR
52959060430	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
52959060530	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
54868520200	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
55289025130	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
55289056630	59250015000350	Aripiprazole Tab 30 MG	ABILIFY	OR
58016005400	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
58016005430	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
58016005460	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
58016005490	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
59148000613	59250015000305	Aripiprazole Tab 2 MG	ABILIFY	OR
59148000713	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
59148000735	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
59148000813	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
59148000835	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
59148000913	59250015000330	Aripiprazole Tab 15 MG	ABILIFY	OR
59148000935	59250015000330	Aripiprazole Tab 15 MG	ABILIFY	OR
59148001013	59250015000340	Aripiprazole Tab 20 MG	ABILIFY	OR
59148001035	59250015000340	Aripiprazole Tab 20 MG	ABILIFY	OR

59148001113	59250015000350	Aripiprazole Tab 30 MG	ABILIFY	OR
59148001135	59250015000350	Aripiprazole Tab 30 MG	ABILIFY	OR
59148001315	59250015002020	Aripiprazole Oral Solution 1 MG/ML	ABILIFY	OR
59148064023	59250015007220	Aripiprazole Orally Disintegrating Tab 10 MG	ABILIFY DISCMELT	OR
59148064123	59250015007230	Aripiprazole Orally Disintegrating Tab 15 MG	ABILIFY DISCMELT	OR
63629338601	59250015000305	Aripiprazole Tab 2 MG	ABILIFY	OR
63629338602	59250015000305	Aripiprazole Tab 2 MG	ABILIFY	OR
63629338604	59250015000305	Aripiprazole Tab 2 MG	ABILIFY	OR
63629338701	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
63629338702	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
63629338703	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
63629338704	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
68071079215	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
68071079315	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
68071079415	59250015000330	Aripiprazole Tab 15 MG	ABILIFY	OR
68258707501	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
68258707601	59250015000330	Aripiprazole Tab 15 MG	ABILIFY	OR
59148000635	59250015000305	Aripiprazole Tab 2 MG	ABILIFY	OR
12280001415	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
12280028215	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
12280028230	59250015000310	Aripiprazole Tab 5 MG	ABILIFY	OR
12280030715	59250015000305	Aripiprazole Tab 2 MG	ABILIFY	OR
12280030730	59250015000305	Aripiprazole Tab 2 MG	ABILIFY	OR
68115046915	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
68115071330	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
68115080415	59250015000330	Aripiprazole Tab 15 MG	ABILIFY	OR
68115080430	59250015000330	Aripiprazole Tab 15 MG	ABILIFY	OR
68258904901	59250015000350	Aripiprazole Tab 30 MG	ABILIFY	OR
49999059815	59250015000320	Aripiprazole Tab 10 MG	ABILIFY	OR
00052011806	59155015100720	Asenapine Maleate SL Tab 5 MG (Base Equiv)	SAPHRIS	SL
00052011890	59155015100720	Asenapine Maleate SL Tab 5 MG (Base Equiv)	SAPHRIS	SL
00052011906	59155015100730	Asenapine Maleate SL Tab 10 MG (Base Equiv)	SAPHRIS	SL
00052011990	59155015100730	Asenapine Maleate SL Tab 10 MG (Base Equiv)	SAPHRIS	SL
00052213903	59155015100720	Asenapine Maleate SL Tab 5 MG (Base Equiv)	SAPHRIS	SL
00052213904	59155015100720	Asenapine Maleate SL Tab 5 MG (Base Equiv)	SAPHRIS	SL
00052214203	59155015100730	Asenapine Maleate SL Tab 10 MG (Base Equiv)	SAPHRIS	SL
00052214204	59155015100730	Asenapine Maleate SL Tab 10 MG (Base Equiv)	SAPHRIS	SL
00247081630	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
00440728530	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
00440728590	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
00440728630	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR

00440728690	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
00781171501	59200015100305	Chlorpromazine HCl Tab 10 MG	CHLORPROMAZINE HCL	OR
00781171513	59200015100305	Chlorpromazine HCl Tab 10 MG	CHLORPROMAZINE HCL	OR
00781171601	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
00781171610	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
00781171701	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
00781171801	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
00781171901	59200015100325	Chlorpromazine HCl Tab 200 MG	CHLORPROMAZINE HCL	OR
00781171910	59200015100325	Chlorpromazine HCl Tab 200 MG	CHLORPROMAZINE HCL	OR
00832030000	59200015100305	Chlorpromazine HCl Tab 10 MG	CHLORPROMAZINE HCL	OR
00832030010	59200015100305	Chlorpromazine HCl Tab 10 MG	CHLORPROMAZINE HCL	OR
00832030100	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
00832030110	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
00832030200	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
00832030210	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
00832030300	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
00832030310	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
00832030400	59200015100325	Chlorpromazine HCl Tab 200 MG	CHLORPROMAZINE HCL	OR
00832030410	59200015100325	Chlorpromazine HCl Tab 200 MG	CHLORPROMAZINE HCL	OR
35356009890	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
51079013001	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
51079013020	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
51079051601	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
51079051620	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
51079051701	59200015100325	Chlorpromazine HCl Tab 200 MG	CHLORPROMAZINE HCL	OR
51079051720	59200015100325	Chlorpromazine HCl Tab 200 MG	CHLORPROMAZINE HCL	OR
51079051801	59200015100305	Chlorpromazine HCl Tab 10 MG	CHLORPROMAZINE HCL	OR
51079051820	59200015100305	Chlorpromazine HCl Tab 10 MG	CHLORPROMAZINE HCL	OR
51079051901	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
51079051920	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
54868230200	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
54868230202	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
54868234700	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
54868246400	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
54868268401	59200015100305	Chlorpromazine HCl Tab 10 MG	CHLORPROMAZINE HCL	OR
60429004230	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
60429004290	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
60429004330	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
60429004390	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
62584033001	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
62584033011	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR

62584033101	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
62584033111	59200015100320	Chlorpromazine HCl Tab 100 MG	CHLORPROMAZINE HCL	OR
63874049401	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049410	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049412	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049414	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049415	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049420	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049421	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049424	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049428	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049430	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049440	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049445	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874049460	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
63874069601	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069610	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069612	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069614	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069615	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069620	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069621	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069624	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069628	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069630	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069640	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
63874069660	59200015100310	Chlorpromazine HCl Tab 25 MG	CHLORPROMAZINE HCL	OR
68084042001	59200015100305	Chlorpromazine HCl Tab 10 MG	CHLORPROMAZINE HCL	OR
68084042011	59200015100305	Chlorpromazine HCl Tab 10 MG	CHLORPROMAZINE HCL	OR
68084042101	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
68084042111	59200015100315	Chlorpromazine HCl Tab 50 MG	CHLORPROMAZINE HCL	OR
68084042201	59200015100325	Chlorpromazine HCl Tab 200 MG	CHLORPROMAZINE HCL	OR
68084042211	59200015100325	Chlorpromazine HCl Tab 200 MG	CHLORPROMAZINE HCL	OR
00121065304	59200025101320	Fluphenazine HCl Oral Conc 5 MG/ML	FLUPHENAZINE HCL	OR
00121065402	59200025101005	Fluphenazine HCl Elixir 2.5 MG/5ML	FLUPHENAZINE HCL	OR
00121065416	59200025101005	Fluphenazine HCl Elixir 2.5 MG/5ML	FLUPHENAZINE HCL	OR
00378600401	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
00378600405	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
00378600901	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
00378600905	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
00378607401	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR

00378607405	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
00378609701	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
00378609705	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
00527178801	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
00527178805	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
00527178901	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
00527178905	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
00527179001	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
00527179005	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
00527179101	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
00527179105	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
00781143601	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
00781143613	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
00781143701	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
00781143801	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
00781143813	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
00781143901	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
51079048501	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
51079048520	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
51079048601	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
51079048620	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
51079048701	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
51079048720	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
51079048801	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
51079048820	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
54868135401	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
54868215600	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
54868215601	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
54868230300	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
58864080240	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
67544093112	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
49884006101	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
49884006105	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
49884006201	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
49884006205	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
49884006401	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
49884006405	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
49884007601	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
49884007605	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
57866440501	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
57866440502	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR

57866440503	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
57866440504	59200025100315	Fluphenazine HCl Tab 5 MG	FLUPHENAZINE HCL	OR
57866440601	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
57866440602	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
57866440603	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
57866440604	59200025100305	Fluphenazine HCl Tab 1 MG	FLUPHENAZINE HCL	OR
57866440701	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
57866440702	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
57866440703	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
57866440704	59200025100310	Fluphenazine HCl Tab 2.5 MG	FLUPHENAZINE HCL	OR
57866440801	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
57866440802	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
57866440803	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
57866440804	59200025100320	Fluphenazine HCl Tab 10 MG	FLUPHENAZINE HCL	OR
00378021401	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
00378021410	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
00378025701	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
00378025710	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
00378032701	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
00378032710	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
00378033401	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
00378033501	59100010100330	Haloperidol Tab 20 MG	HALOPERIDOL	OR
00378035101	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
00378035110	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
00406208001	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
00406208101	59100010100330	Haloperidol Tab 20 MG	HALOPERIDOL	OR
00781139101	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
00781139113	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
00781139201	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
00781139210	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
00781139213	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
00781139301	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
00781139310	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
00781139313	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
00781139601	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
00781139610	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
00781139613	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
00781139701	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
00781139713	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
00781139801	59100010100330	Haloperidol Tab 20 MG	HALOPERIDOL	OR
00904183161	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR

00904592361	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
00904592461	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
00904592561	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
21695065360	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
35356009560	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
47463035190	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
51079043101	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
51079043120	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
51079073301	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
51079073320	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
51079073401	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
51079073420	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
51079073501	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
51079073520	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
51079073601	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
51079073620	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
51079073656	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
52959051810	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
54348012560	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
54868009101	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
54868009102	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
54868009103	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
54868229600	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
54868229601	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
54868229602	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
54868229603	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
54868257000	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
54868257001	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
58016002900	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
58016002930	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
58016002960	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
58016002990	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
58864022215	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
58864073142	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
60429008760	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
60429008860	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
60429008890	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
60429008960	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
60429009060	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
60429009090	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
63874049301	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR

63874049312	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
63874049314	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
63874049315	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
63874049320	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
63874049328	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
63874049330	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
63874049390	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
63874064601	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
63874064612	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
63874064614	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
63874064615	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
63874064620	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
63874064628	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
63874064630	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
63874064660	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
63874065610	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
63874065614	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
63874065615	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
63874065620	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
63874065630	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
63874065660	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
63874083010	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
63874083014	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
63874083060	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
63874100401	59100010100330	Haloperidol Tab 20 MG	HALOPERIDOL	OR
66267084730	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
66336082030	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
66336082130	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
68071049430	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
68084024901	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
68084024911	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
68084025011	59100010100330	Haloperidol Tab 20 MG	HALOPERIDOL	OR
68084025021	59100010100330	Haloperidol Tab 20 MG	HALOPERIDOL	OR
68258707001	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
68258707703	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
68382008001	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
68382008010	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
68382008101	59100010100330	Haloperidol Tab 20 MG	HALOPERIDOL	OR
63739012101	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
63739012103	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
63739012201	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR

63739012303	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
63739012010	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
63739012015	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
63739012115	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
63739012210	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
63739012215	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
63739012315	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
18837034930	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
18837034830	59100010100305	Haloperidol Tab 0.5 MG	HALOPERIDOL	OR
63739012110	59100010100310	Haloperidol Tab 1 MG	HALOPERIDOL	OR
54868230600	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
63739012310	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
57866387801	59100010100315	Haloperidol Tab 2 MG	HALOPERIDOL	OR
57866387901	59100010100320	Haloperidol Tab 5 MG	HALOPERIDOL	OR
57866388001	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
57866388002	59100010100325	Haloperidol Tab 10 MG	HALOPERIDOL	OR
57866388101	59100010100330	Haloperidol Tab 20 MG	HALOPERIDOL	OR
00093960412	59100010201305	Haloperidol Lactate Oral Conc 2 MG/ML	HALOPERIDOL	OR
00093960423	59100010201305	Haloperidol Lactate Oral Conc 2 MG/ML	HALOPERIDOL	OR
00121058104	59100010201305	Haloperidol Lactate Oral Conc 2 MG/ML	HALOPERIDOL	OR
00121058105	59100010201305	Haloperidol Lactate Oral Conc 2 MG/ML	HALOPERIDOL	OR
00603129054	59100010201305	Haloperidol Lactate Oral Conc 2 MG/ML	HALOPERIDOL	OR
54838050115	59100010201305	Haloperidol Lactate Oral Conc 2 MG/ML	HALOPERIDOL	OR
54838050140	59100010201305	Haloperidol Lactate Oral Conc 2 MG/ML	HALOPERIDOL	OR
00182605971	59100010201305	Haloperidol Lactate Oral Conc 2 MG/ML	HALOPERIDOL	OR
43068010102	59070035000310	Iloperidone Tab 1 MG	FANAPT	OR
43068010202	59070035000320	Iloperidone Tab 2 MG	FANAPT	OR
43068010402	59070035000340	Iloperidone Tab 4 MG	FANAPT	OR
43068010602	59070035000360	Iloperidone Tab 6 MG	FANAPT	OR
43068010802	59070035000380	Iloperidone Tab 8 MG	FANAPT	OR
43068011002	59070035000385	Iloperidone Tab 10 MG	FANAPT	OR
43068011202	59070035000390	Iloperidone Tab 12 MG	FANAPT	OR
43068011304	59070035006320	Iloperidone Tab 1 MG & 2 MG & 4 MG & 6 MG Titratration Pak	FANAPT TITRATION PACK	OR
00378700501	59154020200105	Loxapine Succinate Cap 5 MG	LOXAPINE SUCCINATE	OR
00378701001	59154020200110	Loxapine Succinate Cap 10 MG	LOXAPINE SUCCINATE	OR
00378702501	59154020200115	Loxapine Succinate Cap 25 MG	LOXAPINE SUCCINATE	OR
00378705001	59154020200120	Loxapine Succinate Cap 50 MG	LOXAPINE SUCCINATE	OR
00591036901	59154020200105	Loxapine Succinate Cap 5 MG	LOXAPINE SUCCINATE	OR
00591037001	59154020200110	Loxapine Succinate Cap 10 MG	LOXAPINE SUCCINATE	OR
00591037101	59154020200115	Loxapine Succinate Cap 25 MG	LOXAPINE SUCCINATE	OR
00591037201	59154020200120	Loxapine Succinate Cap 50 MG	LOXAPINE SUCCINATE	OR

51079090101	59154020200110	Loxapine Succinate Cap 10 MG	LOXAPINE SUCCINATE	OR
51079090120	59154020200110	Loxapine Succinate Cap 10 MG	LOXAPINE SUCCINATE	OR
51079090201	59154020200115	Loxapine Succinate Cap 25 MG	LOXAPINE SUCCINATE	OR
51079090220	59154020200115	Loxapine Succinate Cap 25 MG	LOXAPINE SUCCINATE	OR
51079090301	59154020200120	Loxapine Succinate Cap 50 MG	LOXAPINE SUCCINATE	OR
51079090320	59154020200120	Loxapine Succinate Cap 50 MG	LOXAPINE SUCCINATE	OR
52544049401	59154020200105	Loxapine Succinate Cap 5 MG	LOXITANE	OR
52544049501	59154020200110	Loxapine Succinate Cap 10 MG	LOXITANE	OR
52544049601	59154020200115	Loxapine Succinate Cap 25 MG	LOXITANE	OR
52544049701	59154020200120	Loxapine Succinate Cap 50 MG	LOXITANE	OR
54868232700	59154020200110	Loxapine Succinate Cap 10 MG	LOXAPINE SUCCINATE	OR
62584089801	59154020200105	Loxapine Succinate Cap 5 MG	LOXAPINE SUCCINATE	OR
62584089811	59154020200105	Loxapine Succinate Cap 5 MG	LOXAPINE SUCCINATE	OR
62584089901	59154020200110	Loxapine Succinate Cap 10 MG	LOXAPINE SUCCINATE	OR
62584089911	59154020200110	Loxapine Succinate Cap 10 MG	LOXAPINE SUCCINATE	OR
62584090201	59154020200115	Loxapine Succinate Cap 25 MG	LOXAPINE SUCCINATE	OR
62584090211	59154020200115	Loxapine Succinate Cap 25 MG	LOXAPINE SUCCINATE	OR
62584090301	59154020200120	Loxapine Succinate Cap 50 MG	LOXAPINE SUCCINATE	OR
62584090311	59154020200120	Loxapine Succinate Cap 50 MG	LOXAPINE SUCCINATE	OR
52152019102	59154020200105	Loxapine Succinate Cap 5 MG	LOXAPINE SUCCINATE	OR
52152019105	59154020200105	Loxapine Succinate Cap 5 MG	LOXAPINE SUCCINATE	OR
52152019202	59154020200110	Loxapine Succinate Cap 10 MG	LOXAPINE SUCCINATE	OR
52152019205	59154020200110	Loxapine Succinate Cap 10 MG	LOXAPINE SUCCINATE	OR
52152019302	59154020200115	Loxapine Succinate Cap 25 MG	LOXAPINE SUCCINATE	OR
52152019305	59154020200115	Loxapine Succinate Cap 25 MG	LOXAPINE SUCCINATE	OR
52152019402	59154020200120	Loxapine Succinate Cap 50 MG	LOXAPINE SUCCINATE	OR
52152019405	59154020200120	Loxapine Succinate Cap 50 MG	LOXAPINE SUCCINATE	OR
63402030401	59400023100320	Lurasidone HCl Tab 40 MG	LATUDA	OR
63402030410	59400023100320	Lurasidone HCl Tab 40 MG	LATUDA	OR
63402030430	59400023100320	Lurasidone HCl Tab 40 MG	LATUDA	OR
63402030801	59400023100340	Lurasidone HCl Tab 80 MG	LATUDA	OR
63402030810	59400023100340	Lurasidone HCl Tab 80 MG	LATUDA	OR
63402030830	59400023100340	Lurasidone HCl Tab 80 MG	LATUDA	OR
68115071000	59160050100315	Molindone HCl Tab 25 MG	MOBAN	OR
63481007470	59160050100315	Molindone HCl Tab 25 MG	MOBAN	OR
63481007670	59160050100320	Molindone HCl Tab 50 MG	MOBAN	OR
63481007270	59160050100305	Molindone HCl Tab 5 MG	MOBAN	OR
63481007370	59160050100310	Molindone HCl Tab 10 MG	MOBAN	OR
00002411201	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
00002411204	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
00002411230	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR

00002411233	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
00002411501	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
00002411504	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
00002411530	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
00002411533	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
00002411601	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
00002411604	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
00002411630	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
00002411633	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
00002411701	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
00002411704	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
00002411730	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
00002411733	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
00002441501	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
00002441504	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
00002441530	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
00002441533	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
00002442001	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
00002442004	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
00002442030	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
00002442033	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
00002445301	59157060007210	Olanzapine Orally Disintegrating Tab 5 MG	ZYPREXA ZYDIS	OR
00002445385	59157060007210	Olanzapine Orally Disintegrating Tab 5 MG	ZYPREXA ZYDIS	OR
00002445401	59157060007220	Olanzapine Orally Disintegrating Tab 10 MG	ZYPREXA ZYDIS	OR
00002445485	59157060007220	Olanzapine Orally Disintegrating Tab 10 MG	ZYPREXA ZYDIS	OR
00002445501	59157060007230	Olanzapine Orally Disintegrating Tab 15 MG	ZYPREXA ZYDIS	OR
00002445585	59157060007230	Olanzapine Orally Disintegrating Tab 15 MG	ZYPREXA ZYDIS	OR
00002445601	59157060007240	Olanzapine Orally Disintegrating Tab 20 MG	ZYPREXA ZYDIS	OR
00002445685	59157060007240	Olanzapine Orally Disintegrating Tab 20 MG	ZYPREXA ZYDIS	OR
13411013401	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
13411013403	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
13411013406	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
13411013409	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
13411013415	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
13411013501	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
13411013503	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
13411013506	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
13411013509	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
13411013515	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
13411013601	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
13411013603	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR

13411013606	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
13411013609	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
13411013615	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
13411013701	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
13411013703	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
13411013706	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
13411013709	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
13411013715	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
13411013801	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
13411013803	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
13411013806	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
13411013809	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
13411013815	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
13411013901	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
13411013903	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
13411013906	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
13411013909	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
13411013915	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
16590051130	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
16590051160	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
16590051172	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
16590051190	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
16590052930	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
16590052960	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
16590052972	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
16590052990	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
16590062130	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
16590062160	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
16590062190	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
16590081830	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
21695014030	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
21695014215	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
21695014430	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
33358037230	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
33358037260	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
35356031630	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
35356031730	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
35356031830	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
35356031930	59157060007210	Olanzapine Orally Disintegrating Tab 5 MG	ZYPREXA ZYDIS	OR
35356032030	59157060007220	Olanzapine Orally Disintegrating Tab 10 MG	ZYPREXA ZYDIS	OR
35356032130	59157060007230	Olanzapine Orally Disintegrating Tab 15 MG	ZYPREXA ZYDIS	OR

35356032230	59157060007240	Olanzapine Orally Disintegrating Tab 20 MG	ZYPREXA ZYDIS	OR
47463054930	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
47463055030	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
47463055130	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
47463055230	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
47463055330	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
49848001530	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
49848001630	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
49848001730	59157060007220	Olanzapine Orally Disintegrating Tab 10 MG	ZYPREXA ZYDIS	OR
49848001830	59157060007210	Olanzapine Orally Disintegrating Tab 5 MG	ZYPREXA ZYDIS	OR
49848002730	59157060007240	Olanzapine Orally Disintegrating Tab 20 MG	ZYPREXA ZYDIS	OR
49848002830	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
49848002930	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
49848003130	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
49999060615	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
49999060630	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
49999073915	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
49999073930	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
52959057930	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
54868394100	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
54868425400	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
54868425401	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
54868425500	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
54868425501	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
54868533600	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
55289021330	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
55289049930	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
58864070430	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
58864076815	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
58864089630	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
58864096815	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
63629363301	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
66105013203	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
66105013206	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
66105013209	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
66105013215	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
66105013245	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
66105013301	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
66105013303	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
66105013306	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
66105013309	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR

66105013315	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
66105013345	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
66105015503	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
66105015506	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
66105015509	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
66105015515	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
66105015545	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
66105055401	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
66105055403	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
66105055406	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
66105055409	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
66105055415	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
67544006430	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
67544006453	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
67544016730	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
67544024830	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
67544024930	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
67544075830	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
68258709001	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
68258709101	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
55887027230	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
55887027260	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
12280002415	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
12280002430	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
12280005830	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
12280005860	59157060000340	Olanzapine Tab 20 MG	ZYPREXA	OR
68115070815	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
68115070830	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
68115070860	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
68115075815	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
68115075830	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
68115075845	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
68115075860	59157060000305	Olanzapine Tab 2.5 MG	ZYPREXA	OR
68115079430	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
68115079460	59157060000315	Olanzapine Tab 7.5 MG	ZYPREXA	OR
68115080330	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
68115080360	59157060000330	Olanzapine Tab 15 MG	ZYPREXA	OR
68115092130	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
68115092160	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
18837037430	59157060000310	Olanzapine Tab 5 MG	ZYPREXA	OR
18837037530	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR

18837037560	59157060000320	Olanzapine Tab 10 MG	ZYPREXA	OR
00002323030	62995002500110	Olanzapine-Fluoxetine HCl Cap 3-25 MG	SYMBYAX	OR
00002323101	62995002500120	Olanzapine-Fluoxetine HCl Cap 6-25 MG	SYMBYAX	OR
00002323130	62995002500120	Olanzapine-Fluoxetine HCl Cap 6-25 MG	SYMBYAX	OR
00002323133	62995002500120	Olanzapine-Fluoxetine HCl Cap 6-25 MG	SYMBYAX	OR
00002323201	62995002500140	Olanzapine-Fluoxetine HCl Cap 12-25 MG	SYMBYAX	OR
00002323230	62995002500140	Olanzapine-Fluoxetine HCl Cap 12-25 MG	SYMBYAX	OR
00002323233	62995002500140	Olanzapine-Fluoxetine HCl Cap 12-25 MG	SYMBYAX	OR
00002323301	62995002500125	Olanzapine-Fluoxetine HCl Cap 6-50 MG	SYMBYAX	OR
00002323330	62995002500125	Olanzapine-Fluoxetine HCl Cap 6-50 MG	SYMBYAX	OR
00002323333	62995002500125	Olanzapine-Fluoxetine HCl Cap 6-50 MG	SYMBYAX	OR
00002323401	62995002500145	Olanzapine-Fluoxetine HCl Cap 12-50 MG	SYMBYAX	OR
00002323430	62995002500145	Olanzapine-Fluoxetine HCl Cap 12-50 MG	SYMBYAX	OR
00002323433	62995002500145	Olanzapine-Fluoxetine HCl Cap 12-50 MG	SYMBYAX	OR
21695045530	59070050007520	Paliperidone Tab SR 24HR 6 MG	INVEGA	OR
35356045030	59070050007510	Paliperidone Tab SR 24HR 3 MG	INVEGA	OR
35356050230	59070050007520	Paliperidone Tab SR 24HR 6 MG	INVEGA	OR
50458055001	59070050007510	Paliperidone Tab SR 24HR 3 MG	INVEGA	OR
50458055010	59070050007510	Paliperidone Tab SR 24HR 3 MG	INVEGA	OR
50458055101	59070050007520	Paliperidone Tab SR 24HR 6 MG	INVEGA	OR
50458055110	59070050007520	Paliperidone Tab SR 24HR 6 MG	INVEGA	OR
50458055201	59070050007530	Paliperidone Tab SR 24HR 9 MG	INVEGA	OR
50458055210	59070050007530	Paliperidone Tab SR 24HR 9 MG	INVEGA	OR
50458055401	59070050007505	Paliperidone Tab SR 24HR 1.5 MG	INVEGA	OR
50458055002	59070050007510	Paliperidone Tab SR 24HR 3 MG	INVEGA	OR
50458055102	59070050007520	Paliperidone Tab SR 24HR 6 MG	INVEGA	OR
50458055202	59070050007530	Paliperidone Tab SR 24HR 9 MG	INVEGA	OR
00247079607	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
00247079614	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
00247079630	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
00247079707	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00247079714	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00247079730	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00247079750	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00247079807	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00247079814	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00247079830	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00247079907	59200045000320	Perphenazine Tab 16 MG	PERPHENAZINE	OR
00247079914	59200045000320	Perphenazine Tab 16 MG	PERPHENAZINE	OR
00247079930	59200045000320	Perphenazine Tab 16 MG	PERPHENAZINE	OR
00440806060	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR

00440806160	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00490009100	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00490009130	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00490009160	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00490009190	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00603509021	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
00603509028	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
00603509121	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00603509128	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00603509221	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00603509228	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00603509321	59200045000320	Perphenazine Tab 16 MG	PERPHENAZINE	OR
00781104601	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
00781104610	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
00781104613	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
00781104701	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00781104710	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00781104713	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00781104801	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00781104810	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00781104813	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00781104901	59200045000320	Perphenazine Tab 16 MG	PERPHENAZINE	OR
00781104913	59200045000320	Perphenazine Tab 16 MG	PERPHENAZINE	OR
21695041460	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
21695041560	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
35356009660	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
52959094060	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
54868268600	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
54868268701	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
54868268702	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
60429015360	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
60429015460	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
62584081701	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
62584081711	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
62584082001	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
62584082011	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
68258707903	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00172367060	59200045000320	Perphenazine Tab 16 MG	PERPHENAZINE	OR
00172366860	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
00172366760	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
00172366960	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR

54738055302	59200045000320	Perphenazine Tab 16 MG	PERPHENAZINE	OR
54738055001	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
54738055002	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
54738055101	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
54738055102	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
54738055201	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
54738055202	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
54738055301	59200045000320	Perphenazine Tab 16 MG	PERPHENAZINE	OR
12280027630	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
12280027660	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
12280027690	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
12280027730	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
12280027760	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
12280027790	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
23629005810	59200045000305	Perphenazine Tab 2 MG	PERPHENAZINE	OR
23629005910	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
57866413201	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
57866413202	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
57866413203	59200045000310	Perphenazine Tab 4 MG	PERPHENAZINE	OR
57866413301	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
57866413302	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
57866413303	59200045000315	Perphenazine Tab 8 MG	PERPHENAZINE	OR
00378004201	62994002600320	Perphenazine-Amitriptyline Tab 4-10 MG	PERPHENAZINE/AMITRIPTYLINE	OR
00378007301	62994002600330	Perphenazine-Amitriptyline Tab 4-50 MG	PERPHENAZINE/AMITRIPTYLINE	OR
00378033001	62994002600310	Perphenazine-Amitriptyline Tab 2-10 MG	PERPHENAZINE/AMITRIPTYLINE	OR
00378033005	62994002600310	Perphenazine-Amitriptyline Tab 2-10 MG	PERPHENAZINE/AMITRIPTYLINE	OR
00378044201	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	PERPHENAZINE/AMITRIPTYLINE	OR
00378044205	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	PERPHENAZINE/AMITRIPTYLINE	OR
00378057401	62994002600325	Perphenazine-Amitriptyline Tab 4-25 MG	PERPHENAZINE/AMITRIPTYLINE	OR
00378057405	62994002600325	Perphenazine-Amitriptyline Tab 4-25 MG	PERPHENAZINE/AMITRIPTYLINE	OR
49999055130	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	PERPHENAZINE/AMITRIPTYLINE	OR
54868392700	62994002600330	Perphenazine-Amitriptyline Tab 4-50 MG	PERPHENAZINE/AMITRIPTYLINE	OR
58016007300	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	PERPHENAZINE/AMITRIPTYLINE	OR
58016007330	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	PERPHENAZINE/AMITRIPTYLINE	OR
58016007360	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	PERPHENAZINE/AMITRIPTYLINE	OR
58016007390	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	PERPHENAZINE/AMITRIPTYLINE	OR
54868012402	62994002600310	Perphenazine-Amitriptyline Tab 2-10 MG	DUO-VIL	OR
54868012403	62994002600310	Perphenazine-Amitriptyline Tab 2-10 MG	DUO-VIL	OR
54868012502	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	DUO-VIL	OR
54868012503	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	DUO-VIL	OR
54868012504	62994002600315	Perphenazine-Amitriptyline Tab 2-25 MG	DUO-VIL	OR

57844015101	62000030000303	Pimozide Tab 1 MG	ORAP	OR
57844018701	62000030000305	Pimozide Tab 2 MG	ORAP	OR
00093964301	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
00093965201	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
00378510501	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
00378511001	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
00440219012	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
00440819006	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
00440819012	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
00440819106	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
00555052204	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
00781502001	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
00781502101	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
10135036701	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
10135036801	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
10135036810	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
16590032710	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
16590032720	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
16590032760	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
21695057130	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
21695057230	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
23490650903	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
23490651201	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
23490651202	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
33261055002	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
33261055030	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
33261055060	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
33261055090	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
33358029920	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
33358029930	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
33358030010	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
33358030020	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
33358030030	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
33358030060	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
35356032500	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
35356032505	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
43063016004	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
43063016006	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
51079054101	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
51079054120	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
51079054201	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR

63874052530	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
66116022620	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
66267027112	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
66267031830	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
66336043406	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
66336043410	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
66336092115	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
66336092160	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
67544039206	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
66993081005	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
49884054901	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
49884055001	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
66993080502	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
66993081002	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
55887039530	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
55887061930	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
51991019601	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
51991019701	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
35356043105	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
68115029800	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
68115029804	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
68115029812	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
68115029815	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
68115029830	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
68115029860	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
68115029890	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
68115030010	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
68115030030	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
00555052102	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
00555052202	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
57866018901	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
57866629801	59200055100310	Prochlorperazine Maleate Tab 10 MG	PROCHLORPERAZINE MALEATE	OR
57866629901	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
57866629902	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
57866629903	59200055100305	Prochlorperazine Maleate Tab 5 MG	PROCHLORPERAZINE MALEATE	OR
00310027110	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
00310027139	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
00310027210	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
00310027239	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
00310027439	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
00310027460	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR

00310027510	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
00310027534	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
00310027539	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
00310027810	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
00310027834	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
00310027839	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
00310027910	59153070100350	Quetiapine Fumarate Tab 400 MG	SEROQUEL	OR
00310027939	59153070100350	Quetiapine Fumarate Tab 400 MG	SEROQUEL	OR
00310028039	59153070107505	Quetiapine Fumarate Tab SR 24HR 50 MG	SEROQUEL XR	OR
00310028060	59153070107505	Quetiapine Fumarate Tab SR 24HR 50 MG	SEROQUEL XR	OR
00310028139	59153070107515	Quetiapine Fumarate Tab SR 24HR 150 MG	SEROQUEL XR	OR
00310028160	59153070107515	Quetiapine Fumarate Tab SR 24HR 150 MG	SEROQUEL XR	OR
00310028239	59153070107520	Quetiapine Fumarate Tab SR 24HR 200 MG	SEROQUEL XR	OR
00310028260	59153070107520	Quetiapine Fumarate Tab SR 24HR 200 MG	SEROQUEL XR	OR
00310028339	59153070107530	Quetiapine Fumarate Tab SR 24HR 300 MG	SEROQUEL XR	OR
00310028360	59153070107530	Quetiapine Fumarate Tab SR 24HR 300 MG	SEROQUEL XR	OR
00310028439	59153070107540	Quetiapine Fumarate Tab SR 24HR 400 MG	SEROQUEL XR	OR
00310028460	59153070107540	Quetiapine Fumarate Tab SR 24HR 400 MG	SEROQUEL XR	OR
13411012701	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
13411012703	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
13411012706	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
13411012709	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
13411012715	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
13411012801	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
13411012803	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
13411012806	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
13411012809	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
13411012815	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
13411012901	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
13411012903	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
13411012906	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
13411012909	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
13411012915	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
13411013001	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
13411013003	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
13411013006	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
13411013009	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
13411013015	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
16590051930	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
16590051960	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
16590051972	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR

16590051990	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
16590052030	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
16590052060	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
16590052072	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
16590052090	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
16590052130	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
16590052160	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
16590052172	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
16590052190	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
16590067930	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
16590067960	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
16590067990	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
16590078230	59153070100350	Quetiapine Fumarate Tab 400 MG	SEROQUEL	OR
21695011715	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
21695011815	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
21695011915	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
21695011930	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
21695012015	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
33358032030	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
33358032060	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
35356008600	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
35356008630	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
35356020460	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
35356026100	59153070107540	Quetiapine Fumarate Tab SR 24HR 400 MG	SEROQUEL XR	OR
35356026130	59153070107540	Quetiapine Fumarate Tab SR 24HR 400 MG	SEROQUEL XR	OR
35356044030	59153070107520	Quetiapine Fumarate Tab SR 24HR 200 MG	SEROQUEL XR	OR
35356044130	59153070107530	Quetiapine Fumarate Tab SR 24HR 300 MG	SEROQUEL XR	OR
35356044230	59153070107540	Quetiapine Fumarate Tab SR 24HR 400 MG	SEROQUEL XR	OR
47463075130	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
47463075260	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
47463075360	59153070107515	Quetiapine Fumarate Tab SR 24HR 150 MG	SEROQUEL XR	OR
47463075460	59153070107520	Quetiapine Fumarate Tab SR 24HR 200 MG	SEROQUEL XR	OR
47463075560	59153070107530	Quetiapine Fumarate Tab SR 24HR 300 MG	SEROQUEL XR	OR
47463075660	59153070107540	Quetiapine Fumarate Tab SR 24HR 400 MG	SEROQUEL XR	OR
49848001200	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
49848001300	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
49848001400	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
49848002600	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
49848003030	59153070100350	Quetiapine Fumarate Tab 400 MG	SEROQUEL	OR
49999060200	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
49999060215	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR

49999060230	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
49999060300	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
49999060315	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
49999060330	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
49999095130	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
54569569101	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
54569570700	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
54868425700	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
54868425701	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
54868425702	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
54868425703	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
54868425704	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
54868427200	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
54868427201	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
54868496100	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
54868496101	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
54868496102	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
54868496103	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
54868496104	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
54868548400	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
54868548401	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
54868558100	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
54868558101	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
54868558102	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
54868558103	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
55289018730	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
55289044730	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
55289087230	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
58016004600	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
58016004630	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
58016004660	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
58016004690	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
58864073830	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
58864073860	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
58864088830	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
58864095930	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
58864096130	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
63629329101	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
63629329102	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
63629331901	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
63629331902	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR

63629331903	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
63629337801	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
63629337802	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
63629337803	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
63629337804	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
63629337805	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
63629337901	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
63629337902	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
63629337903	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
63629337904	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
63629338001	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
63629338002	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
63629338003	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
63629338004	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
66105014001	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
66105014003	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
66105014006	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
66105014009	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
66105014010	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
66105014101	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
66105014103	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
66105014106	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
66105014109	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
66105014110	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
66105014201	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
66105014203	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
66105014206	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
66105014209	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
66105014210	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
67544015530	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
67544015553	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
67544019615	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
67544019630	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
67544019682	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
67544019688	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
67544019699	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
67544028130	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
67544028153	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
67544028182	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
67544028199	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
68071032930	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR

68071032960	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
68071041330	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
68071042830	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
68258711001	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
68258711101	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
68258711201	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
68258711301	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
54569569201	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
54569569301	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
00310028455	59153070107540	Quetiapine Fumarate Tab SR 24HR 400 MG	SEROQUEL XR	OR
00310028255	59153070107520	Quetiapine Fumarate Tab SR 24HR 200 MG	SEROQUEL XR	OR
00310028355	59153070107530	Quetiapine Fumarate Tab SR 24HR 300 MG	SEROQUEL XR	OR
12280002015	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
12280003015	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
12280003030	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
12280004160	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
12280028015	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
12280028060	59153070100340	Quetiapine Fumarate Tab 300 MG	SEROQUEL	OR
12280039630	59153070100350	Quetiapine Fumarate Tab 400 MG	SEROQUEL	OR
68115084200	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
68115088600	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
68115088615	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
68115091200	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
68115091215	59153070100330	Quetiapine Fumarate Tab 200 MG	SEROQUEL	OR
18837014330	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
18837014360	59153070100310	Quetiapine Fumarate Tab 25 MG	SEROQUEL	OR
18837014130	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
18837014160	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
18837014198	59153070100320	Quetiapine Fumarate Tab 100 MG	SEROQUEL	OR
18837034690	59153070100314	Quetiapine Fumarate Tab 50 MG	SEROQUEL	OR
00054006344	59070070002010	Risperidone Soln 1 MG/ML	RISPERIDONE	OR
00093022105	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
00093022106	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
00093022505	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
00093022506	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
00093724005	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00093724006	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00093724105	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00093724106	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00093724205	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
00093724206	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR

00093724306	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
00378350205	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
00378350291	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
00378350505	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
00378350591	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
00378351105	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00378351191	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00378351205	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00378351291	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00378351305	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
00378351391	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
00378351491	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
00555177104	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00555177109	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00555177204	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00555177209	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00555177304	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
00555177309	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
00555177409	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
00603568320	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
00603568328	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
00603568420	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
00603568428	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
00603568432	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
00603568520	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00603568528	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00603568532	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00603568620	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00603568628	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00603568632	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00603568820	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
00603568828	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
00603568920	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
00603568928	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
00781531008	59070070007220	Risperidone Orally Disintegrating Tab 0.5 MG	RISPERIDONE ODT	OR
00781531108	59070070007230	Risperidone Orally Disintegrating Tab 1 MG	RISPERIDONE ODT	OR
00781531208	59070070007240	Risperidone Orally Disintegrating Tab 2 MG	RISPERIDONE ODT	OR
00781531308	59070070007250	Risperidone Orally Disintegrating Tab 3 MG	RISPERIDONE ODT	OR
00781531408	59070070007260	Risperidone Orally Disintegrating Tab 4 MG	RISPERIDONE ODT	OR
00904597361	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
00904597461	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR

00904597561	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
00904597661	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
00904597761	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
00904597861	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
13411012301	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
13411012303	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
13411012306	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
13411012309	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
13411012315	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
13411012401	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
13411012403	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
13411012406	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
13411012409	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
13411012415	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
13668003501	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
13668003505	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
13668003560	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
13668003571	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
13668003574	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
13668003601	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
13668003605	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
13668003660	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
13668003671	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
13668003674	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
13668003701	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
13668003705	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
13668003760	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
13668003771	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
13668003774	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
13668003801	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
13668003805	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
13668003860	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
13668003871	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
13668003874	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
13668003901	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
13668003905	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
13668003960	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
13668003971	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
13668003974	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
13668004001	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
13668004005	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR

13668004060	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
13668004064	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
13668004071	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
13668004074	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
16252055860	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
16252055960	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
16252056060	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
16252056160	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
16252056260	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
16252056360	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
16590038930	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
16590038960	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
16590039030	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
16590039060	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
16590057230	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
16590057260	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
16590057530	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
16590057560	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
16590064130	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
16590064160	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
16590064190	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
16590081130	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
16590081160	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
21695007260	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
21695008760	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
21695008960	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
21695009560	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
21695009660	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
21695011315	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
21695011530	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
21695011560	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
21695014160	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
33358031830	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
33358031860	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
35356010660	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
42769133101	59070070002010	Risperidone Soln 1 MG/ML	RISPERIDONE	OR
43063025430	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43063025460	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353040115	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353040130	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353040140	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR

43353040145	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353040160	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353040330	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353040345	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353040360	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353041215	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353041230	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353041245	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353041260	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353043230	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353043245	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353043260	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353045015	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353045030	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353045045	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353045060	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353046030	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353046045	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353046060	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353054330	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353054345	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353054360	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
43353055015	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353055030	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353055045	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353055060	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
43353063915	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
43353063930	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
49884021255	59070070007210	Risperidone Orally Disintegrating Tab 0.25 MG	RISPERIDONE ODT	OR
49884031155	59070070007220	Risperidone Orally Disintegrating Tab 0.5 MG	RISPERIDONE ODT	OR
49884031191	59070070007220	Risperidone Orally Disintegrating Tab 0.5 MG	RISPERIDONE ODT	OR
49884031555	59070070007230	Risperidone Orally Disintegrating Tab 1 MG	RISPERIDONE ODT	OR
49884031591	59070070007230	Risperidone Orally Disintegrating Tab 1 MG	RISPERIDONE ODT	OR
49884040191	59070070007240	Risperidone Orally Disintegrating Tab 2 MG	RISPERIDONE ODT	OR
49884040291	59070070007250	Risperidone Orally Disintegrating Tab 3 MG	RISPERIDONE ODT	OR
49884040391	59070070007260	Risperidone Orally Disintegrating Tab 4 MG	RISPERIDONE ODT	OR
49999063315	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
49999063430	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
49999063460	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
49999077560	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
49999091115	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR

50458030001	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
50458030006	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
50458030050	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
50458030101	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
50458030104	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
50458030150	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
50458030201	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
50458030206	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
50458030250	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
50458030503	59070070002010	Risperidone Soln 1 MG/ML	RISPERDAL	OR
50458031528	59070070007230	Risperidone Orally Disintegrating Tab 1 MG	RISPERDAL M-TAB	OR
50458031530	59070070007230	Risperidone Orally Disintegrating Tab 1 MG	RISPERDAL M-TAB	OR
50458032001	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
50458032006	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
50458032050	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
50458032528	59070070007240	Risperidone Orally Disintegrating Tab 2 MG	RISPERDAL M-TAB	OR
50458033001	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
50458033006	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
50458033050	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
50458033528	59070070007250	Risperidone Orally Disintegrating Tab 3 MG	RISPERDAL M-TAB	OR
50458035001	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
50458035006	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
50458035528	59070070007260	Risperidone Orally Disintegrating Tab 4 MG	RISPERDAL M-TAB	OR
50458039528	59070070007220	Risperidone Orally Disintegrating Tab 0.5 MG	RISPERDAL M-TAB	OR
50458039530	59070070007220	Risperidone Orally Disintegrating Tab 0.5 MG	RISPERDAL M-TAB	OR
50458059010	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
50458059050	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
50458059060	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
50458059110	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
50458059150	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
50458059160	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
50458059210	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
50458059250	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
50458059260	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
50458059310	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
50458059350	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
50458059360	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
50458059410	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
50458059450	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
50458059460	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
50458059510	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR

50458059560	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
50458059601	59070070002010	Risperidone Soln 1 MG/ML	RISPERIDONE	OR
50458060128	59070070007220	Risperidone Orally Disintegrating Tab 0.5 MG	RISPERIDONE M-TAB	OR
50458060228	59070070007230	Risperidone Orally Disintegrating Tab 1 MG	RISPERIDONE M-TAB	OR
50458060328	59070070007240	Risperidone Orally Disintegrating Tab 2 MG	RISPERIDONE M-TAB	OR
50458060428	59070070007250	Risperidone Orally Disintegrating Tab 3 MG	RISPERIDONE M-TAB	OR
50458060528	59070070007260	Risperidone Orally Disintegrating Tab 4 MG	RISPERIDONE M-TAB	OR
51079046001	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
51079046020	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
51079046101	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
51079046120	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
51079046201	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
51079046220	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
51079046230	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
51079046256	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
51079046301	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
51079046320	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
51079046330	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
51079046356	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
51079046401	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
51079046420	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
51079046430	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
51079046456	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
51079046501	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
51079046520	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
51079046530	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
51079046556	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
51129462402	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
52959021960	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
52959091630	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
52959091660	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
52959094130	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
54569414001	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
54868351200	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
54868351201	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
54868351301	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
54868351302	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
54868351400	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
54868351500	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
54868487400	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
54868580000	59070070002010	Risperidone Soln 1 MG/ML	RISPERDAL	OR

54868591800	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
54868608200	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
54868620100	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
55111020105	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
55111020160	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
55111020205	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
55111020260	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
55111020305	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
55111020360	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
55111020405	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
55111020460	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
55111020505	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
55111020560	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
55111020660	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
55111020781	59070070007220	Risperidone Orally Disintegrating Tab 0.5 MG	RISPERIDONE ODT	OR
55111020881	59070070007230	Risperidone Orally Disintegrating Tab 1 MG	RISPERIDONE ODT	OR
55111020981	59070070007240	Risperidone Orally Disintegrating Tab 2 MG	RISPERIDONE ODT	OR
55111047081	59070070007250	Risperidone Orally Disintegrating Tab 3 MG	RISPERIDONE ODT	OR
55111047181	59070070007260	Risperidone Orally Disintegrating Tab 4 MG	RISPERIDONE ODT	OR
55111057930	59070070002010	Risperidone Soln 1 MG/ML	RISPERIDONE	OR
55289046330	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
55289046530	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
55289049130	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
55289051930	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
58016004900	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
58016004930	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
58016004960	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
58016004990	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
58016005000	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
58016005030	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
58016005060	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
58016005090	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
58864003830	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
60505038001	59070070002010	Risperidone Soln 1 MG/ML	RISPERIDONE	OR
60505258400	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
60505258405	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
60505258406	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
60505258500	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
60505258505	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
60505258506	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
60505258600	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR

60505258605	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
60505258606	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
60505258700	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
60505258705	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
60505258706	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
60505258800	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
60505258805	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
60505258806	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
60505258900	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
60505258906	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
64679055302	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
64679055304	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
64679055402	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
64679055404	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
64679055502	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
64679055504	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
64679055702	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
64679055704	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
64679057102	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
64679057104	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
64679057202	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
64679057204	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
64679069201	59070070002010	Risperidone Soln 1 MG/ML	RISPERIDONE	OR
65862011905	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
65862011960	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
65862012005	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
65862012060	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
65862012105	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
65862012160	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
65862012205	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
65862012260	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
65862012305	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
65862012360	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
65862012460	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
65862016730	59070070002010	Risperidone Soln 1 MG/ML	RISPERIDONE	OR
66105012301	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
66105012303	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
66105012306	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
66105012309	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
66105012315	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
66105012401	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR

66105012403	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
66105012406	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
66105012409	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
66105012415	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
66105012501	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
66105012503	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
66105012506	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
66105012509	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
66105012515	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
67544006715	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
67544006730	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
67544006745	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
67544006748	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
67544006760	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
67544006789	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
67544021015	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
67544021030	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
67544021045	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
67544021060	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
67544021130	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
67544021160	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
68084027001	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
68084027011	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
68084027101	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
68084027111	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
68084027201	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
68084027211	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
68084027301	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
68084027311	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
68084027401	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
68084027411	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
68084027701	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
68084027711	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
68258712001	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
68258712101	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
68258712201	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
68382011205	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
68382011214	59070070000303	Risperidone Tab 0.25 MG	RISPERIDONE	OR
68382011305	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
68382011314	59070070000306	Risperidone Tab 0.5 MG	RISPERIDONE	OR
68382011405	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR

68382011414	59070070000310	Risperidone Tab 1 MG	RISPERIDONE	OR
68382011505	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
68382011514	59070070000320	Risperidone Tab 2 MG	RISPERIDONE	OR
68382011605	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
68382011614	59070070000330	Risperidone Tab 3 MG	RISPERIDONE	OR
68382011705	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
68382011714	59070070000340	Risperidone Tab 4 MG	RISPERIDONE	OR
68382015406	59070070007220	Risperidone Orally Disintegrating Tab 0.5 MG	RISPERIDONE ODT	OR
68382015506	59070070007230	Risperidone Orally Disintegrating Tab 1 MG	RISPERIDONE ODT	OR
68382015606	59070070007240	Risperidone Orally Disintegrating Tab 2 MG	RISPERIDONE ODT	OR
12280001915	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
12280038415	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
12280038460	59070070000340	Risperidone Tab 4 MG	RISPERDAL	OR
68115069415	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
68115069460	59070070000303	Risperidone Tab 0.25 MG	RISPERDAL	OR
68115078315	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
68115078330	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
68115078360	59070070000330	Risperidone Tab 3 MG	RISPERDAL	OR
68115082715	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
68115082760	59070070000306	Risperidone Tab 0.5 MG	RISPERDAL	OR
68115085615	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
68115085660	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
68115092860	59070070000310	Risperidone Tab 1 MG	RISPERDAL	OR
18837033560	59070070000320	Risperidone Tab 2 MG	RISPERDAL	OR
00093616931	59070070002010	Risperidone Soln 1 MG/ML	RISPERIDONE	OR
00378061201	59200080100305	Thioridazine HCl Tab 10 MG	THIORIDAZINE HCL	OR
00378061210	59200080100305	Thioridazine HCl Tab 10 MG	THIORIDAZINE HCL	OR
00378061401	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
00378061410	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
00378061601	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
00378061610	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
00378061801	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR
00378061810	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR
51079056501	59200080100305	Thioridazine HCl Tab 10 MG	THIORIDAZINE HCL	OR
51079056520	59200080100305	Thioridazine HCl Tab 10 MG	THIORIDAZINE HCL	OR
51079056601	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
51079056620	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
51079056701	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
51079056720	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
51079058001	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR
51079058020	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR

53489014801	59200080100305	Thioridazine HCl Tab 10 MG	THIORIDAZINE HCL	OR
53489014810	59200080100305	Thioridazine HCl Tab 10 MG	THIORIDAZINE HCL	OR
53489014901	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
53489014910	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
53489015001	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
53489015010	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
53489050001	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR
54868006700	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
54868006704	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
54868006705	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
54868182800	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR
54868182802	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR
54868183200	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
54868183202	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
54868183203	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
00677082301	59200080100305	Thioridazine HCl Tab 10 MG	THIORIDAZINE HCL	OR
00677082501	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
00677082401	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
00677083201	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR
00677083206	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR
57866104201	59200080100305	Thioridazine HCl Tab 10 MG	THIORIDAZINE HCL	OR
57866464203	59200080100315	Thioridazine HCl Tab 25 MG	THIORIDAZINE HCL	OR
57866464301	59200080100320	Thioridazine HCl Tab 50 MG	THIORIDAZINE HCL	OR
57866464401	59200080100325	Thioridazine HCl Tab 100 MG	THIORIDAZINE HCL	OR
00049572066	59300020100110	Thiothixene Cap 2 MG	NAVANE	OR
00049574066	59300020100120	Thiothixene Cap 10 MG	NAVANE	OR
00049577066	59300020100125	Thiothixene Cap 20 MG	NAVANE	OR
00378100101	59300020100105	Thiothixene Cap 1 MG	THIOTHIXENE	OR
00378200201	59300020100110	Thiothixene Cap 2 MG	THIOTHIXENE	OR
00378200210	59300020100110	Thiothixene Cap 2 MG	THIOTHIXENE	OR
00378300501	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
00378300510	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
00378501001	59300020100120	Thiothixene Cap 10 MG	THIOTHIXENE	OR
00378501010	59300020100120	Thiothixene Cap 10 MG	THIOTHIXENE	OR
00781222601	59300020100105	Thiothixene Cap 1 MG	THIOTHIXENE	OR
00781222701	59300020100110	Thiothixene Cap 2 MG	THIOTHIXENE	OR
00781222713	59300020100110	Thiothixene Cap 2 MG	THIOTHIXENE	OR
00781222801	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
00781222901	59300020100120	Thiothixene Cap 10 MG	THIOTHIXENE	OR
21695016130	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
51079058701	59300020100110	Thiothixene Cap 2 MG	THIOTHIXENE	OR

51079058720	59300020100110	Thiothixene Cap 2 MG	THIOTHIXENE	OR
51079058801	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
51079058820	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
51079058901	59300020100120	Thiothixene Cap 10 MG	THIOTHIXENE	OR
51079058920	59300020100120	Thiothixene Cap 10 MG	THIOTHIXENE	OR
54868234300	59300020100110	Thiothixene Cap 2 MG	THIOTHIXENE	OR
54868235800	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
51079058601	59300020100105	Thiothixene Cap 1 MG	THIOTHIXENE	OR
51079058620	59300020100105	Thiothixene Cap 1 MG	THIOTHIXENE	OR
00049573066	59300020100115	Thiothixene Cap 5 MG	NAVANE	OR
57866443701	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
57866443702	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
57866443703	59300020100115	Thiothixene Cap 5 MG	THIOTHIXENE	OR
57866443801	59300020100120	Thiothixene Cap 10 MG	THIOTHIXENE	OR
57866443802	59300020100120	Thiothixene Cap 10 MG	THIOTHIXENE	OR
57866443803	59300020100120	Thiothixene Cap 10 MG	THIOTHIXENE	OR
00378240101	59200085100305	Trifluoperazine HCl Tab 1 MG	TRIFLUOPERAZINE HCL	OR
00378240201	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR
00378240501	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
00378241001	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
00781103001	59200085100305	Trifluoperazine HCl Tab 1 MG	TRIFLUOPERAZINE HCL	OR
00781103201	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR
00781103401	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
00781103601	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
00781103610	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
00781103613	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
16590030530	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR
51079057201	59200085100305	Trifluoperazine HCl Tab 1 MG	TRIFLUOPERAZINE HCL	OR
51079057220	59200085100305	Trifluoperazine HCl Tab 1 MG	TRIFLUOPERAZINE HCL	OR
51079057301	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR
51079057320	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR
51079057401	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
51079057420	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
51079057501	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
51079057520	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
54868135200	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
54868235601	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
60429019218	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR
60429019230	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR
60429019260	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR
60429019290	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR

60429019318	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
60429019330	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
60429019360	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
60429019390	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
60429019430	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
68071080730	59200085100310	Trifluoperazine HCl Tab 2 MG	TRIFLUOPERAZINE HCL	OR
68115058600	59200085100315	Trifluoperazine HCl Tab 5 MG	TRIFLUOPERAZINE HCL	OR
57866443901	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
57866443902	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
57866443903	59200085100320	Trifluoperazine HCl Tab 10 MG	TRIFLUOPERAZINE HCL	OR
00049396041	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
00049396060	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
00049397041	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
00049397060	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
00049398041	59400085100140	Ziprasidone HCl Cap 60 MG	GEODON	OR
00049398060	59400085100140	Ziprasidone HCl Cap 60 MG	GEODON	OR
00049399041	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
00049399060	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
16590075830	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
16590075860	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
16590081660	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
16590089530	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
16590089560	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
21695006010	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
21695006015	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
21695006045	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
21695006115	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
21695006145	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
21695006260	59400085100140	Ziprasidone HCl Cap 60 MG	GEODON	OR
21695006360	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
35356009760	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
35356027460	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
49848002460	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
49999062060	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
49999062160	59400085100140	Ziprasidone HCl Cap 60 MG	GEODON	OR
54868454400	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
54868548500	59400085100140	Ziprasidone HCl Cap 60 MG	GEODON	OR
54868560500	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
54868560601	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
58864095830	59400085100140	Ziprasidone HCl Cap 60 MG	GEODON	OR
58864096030	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR

58864096230	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
58864096430	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
63874100606	59400085100140	Ziprasidone HCl Cap 60 MG	GEODON	OR
63874100701	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
63874100706	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
63874100806	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
68071060815	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
68071079515	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
68258707201	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
68258707301	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
12280041360	59400085100140	Ziprasidone HCl Cap 60 MG	GEODON	OR
68115067060	59400085100150	Ziprasidone HCl Cap 80 MG	GEODON	OR
68115081815	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
68115081830	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
68115081860	59400085100120	Ziprasidone HCl Cap 20 MG	GEODON	OR
68115093015	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
68115093030	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
68115093045	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR
68115093060	59400085100130	Ziprasidone HCl Cap 40 MG	GEODON	OR

Clozapine for Exclusion

ndc_code	drug_id	generic_product_name	Brand_Name	Route
00078012605	59152020000320	Clozapine Tab 25 MG	CLOZARIL	OR
00078012606	59152020000320	Clozapine Tab 25 MG	CLOZARIL	OR
00078012705	59152020000330	Clozapine Tab 100 MG	CLOZARIL	OR
00078012706	59152020000330	Clozapine Tab 100 MG	CLOZARIL	OR
00093435901	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
00093435905	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
00093435919	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
00093435993	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
00093440401	59152020000325	Clozapine Tab 50 MG	CLOZAPINE	OR
00093440405	59152020000325	Clozapine Tab 50 MG	CLOZAPINE	OR
00093440419	59152020000325	Clozapine Tab 50 MG	CLOZAPINE	OR
00093440493	59152020000325	Clozapine Tab 50 MG	CLOZAPINE	OR
00093440501	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
00093440505	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
00093440519	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
00093440593	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
00093777201	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00093777205	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR

00093777219	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00093777293	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00378082501	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
00378086001	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00378086005	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00378097201	59152020000325	Clozapine Tab 50 MG	CLOZAPINE	OR
00378097301	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
00378097305	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
00440731560	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
00440731790	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00440731791	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
18860010110	59152020007210	Clozapine Orally Disintegrating Tab 12.5 MG	FAZACLO	OR
18860010201	59152020007220	Clozapine Orally Disintegrating Tab 25 MG	FAZACLO	OR
18860010210	59152020007220	Clozapine Orally Disintegrating Tab 25 MG	FAZACLO	OR
18860010401	59152020007230	Clozapine Orally Disintegrating Tab 100 MG	FAZACLO	OR
18860010410	59152020007230	Clozapine Orally Disintegrating Tab 100 MG	FAZACLO	OR
18860010501	59152020007240	Clozapine Orally Disintegrating Tab 150 MG	FAZACLO	OR
18860010510	59152020007240	Clozapine Orally Disintegrating Tab 150 MG	FAZACLO	OR
18860010601	59152020007250	Clozapine Orally Disintegrating Tab 200 MG	FAZACLO	OR
18860010610	59152020007250	Clozapine Orally Disintegrating Tab 200 MG	FAZACLO	OR
51079074901	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
51079074920	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
51079092101	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
51079092120	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
51079092201	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
51079092220	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
57664024188	59152020000325	Clozapine Tab 50 MG	CLOZAPINE	OR
57664034513	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
57664034588	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
57664034713	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
57664034788	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
68084023301	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
68084023311	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
68084023401	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
68084023411	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00172440460	59152020000325	Clozapine Tab 50 MG	CLOZAPINE	OR
00172440470	59152020000325	Clozapine Tab 50 MG	CLOZAPINE	OR
00172435960	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
00172436070	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00172440560	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
00172440570	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR

00172435970	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
00172440410	59152020000325	Clozapine Tab 50 MG	CLOZAPINE	OR
00172440510	59152020000340	Clozapine Tab 200 MG	CLOZAPINE	OR
00172436060	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00172436000	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00172436010	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00172435900	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
00172435910	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
49884008801	59152020000320	Clozapine Tab 25 MG	CLOZAPINE	OR
49884008901	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
49884008905	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
68322000104	59152020007220	Clozapine Orally Disintegrating Tab 25 MG	FAZACLO	OR
68322000204	59152020007230	Clozapine Orally Disintegrating Tab 100 MG	FAZACLO	OR
64597010410	59152020007230	Clozapine Orally Disintegrating Tab 100 MG	FAZACLO	OR
68322000102	59152020007220	Clozapine Orally Disintegrating Tab 25 MG	FAZACLO	OR
68322000202	59152020007230	Clozapine Orally Disintegrating Tab 100 MG	FAZACLO	OR
64597010210	59152020007220	Clozapine Orally Disintegrating Tab 25 MG	FAZACLO	OR
64597010110	59152020007210	Clozapine Orally Disintegrating Tab 12.5 MG	FAZACLO	OR
00093436001	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00093436005	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00093436019	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR
00093436093	59152020000330	Clozapine Tab 100 MG	CLOZAPINE	OR

Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Table 1a. Reliability Results

Unit of Analysis	Percent Agreement*		Final Cohen's Kappa
	Programmer 1 Num/Den (%)	Programmer 2 Num/Den (%)	
FL	7,339/82,298 (8.9%)	6,707/82,298 (8.2%)	0.95
RI	660/6,597 (10.0%)	623/6,597 (9.4%)	0.97
Part D Plan 1	8/316 (2.5%)	8/316 (2.5%)	1.00
Part D Plan 2	33/338 (9.8%)	31/338 (9.2%)	0.97
Part D Plan 3	1,497/12,863 (11.6%)	1,392/12,863 (10.8%)	0.96
Part D Plan 4	9/162 (5.6%)	8/162 (4.9%)	0.94
Part D Plan 5	78/521 (15.0%)	76/521 (14.6%)	0.98
Physician Group 1	5/44 (11.4%)	5/44 (11.4%)	1.00
Physician Group 2	15/58 (25.9%)	13/58 (22.4%)	0.91
Physician Group 3	21/63 (33.3%)	19/63 (30.2%)	0.93
Physician Group 4	2/34 (5.9%)	2/34 (5.9%)	1.00
Physician Group 5	6/122 (4.9%)	5/122 (4.1%)	0.90

Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Formula 1.

$$\text{reliability} = \frac{\sigma_{\text{physician group-to-physician group}}^2}{\sigma_{\text{physician group-to-physician group}}^2 + \sigma_{\text{physician-specific-error}}^2}$$

Formula 2.

$$\sigma_{\text{physician group-to-physician group}}^2 = \frac{\alpha\beta}{(\alpha + \beta + 1)(\alpha + \beta)^2}$$

Formula 3.

$$\sigma_{\text{physician-specific-error}}^2 = \frac{\hat{p}(1 - \hat{p})}{n}$$

With $\hat{p} = \frac{x + \hat{\alpha}}{n + \hat{\alpha} + \hat{\beta}} = \frac{n}{n + \hat{\alpha} + \hat{\beta}} \cdot \frac{x}{n} + \frac{\hat{\alpha} + \hat{\beta}}{n + \hat{\alpha} + \hat{\beta}} \cdot \frac{\hat{\alpha}}{\hat{\alpha} + \hat{\beta}}$

Where x=numerator

n=denominator

$\hat{\alpha}, \hat{\beta}$ =parameters of Beta distribution estimated from the macro.

The right hand of the formula shows that the estimator is a weighted average of the physician sample

mean $\frac{x}{n}$ and the average physician mean $\frac{\hat{\alpha}}{\hat{\alpha} + \hat{\beta}}$ (mean of the Beta distribution), which shrinks to the average physician mean.

Table 1b. Plan Reliability Scores

Total Part D Plans with at least 30 patients attributed	244
Denominator threshold in which 90% of physician groups have a reliability of ≥ 0.7	145
Part D Plans with reliability ≥ 0.7	156 (63.9%)

Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Figure 1a: Part D Plan Reliability by Denominator Size





Table 1c. Physician Group Reliability Scores

Total physician groups with at least 30 patients attributed	365
Denominator threshold in which 90% of physician groups have a reliability of ≥ 0.7	137
Physician groups with reliability ≥ 0.7	54 (14.5%)

Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Figure 1b. Physician Group Reliability Score by Denominator Size



Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Table 2. Distribution of Denominator Sizes and Measure Scores Across Part D Plan with ≥ 30 Beneficiaries

Across Part D Plan with ≥ 30 Beneficiaries	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5
Number of plans	25	26	26	26	25
Denominator size range (minimum-maximum)	32-670	32-1,820	36-4,859	30-19,727	34-22,941
Median denominator size	85	209±5	113	252	1645
Measure score (95% CI) of the plan with a denominator size closest to the median denominator size	2.4% (0.3-8.2)	4.0% (1.9-7.4)	4.5% (1.5-10.2)	8.7% (5.6-12.9)	9.5% (8.1-11.0)
Measure score range (minimum-maximum)	0.0%-2.9%	2.9%-4.3%	4.4%-6.3%	6.3%-8.8%	8.8%-24.0%
Median measure score	2.1%	3.8%	5.1%	7.6%	10.6%
Measure score (95% CI) of the plan with a score closest to the median score	2.1% (1.2-3.5)	3.8% (0.5-13.2)	5.1% (4.1-6.3)	7.6% (6.1-9.4)	10.6% (9.9-11.3)
95% CI based on using the median denominator size N=198	2.1% (0.6-5.2)	3.8% (1.6-7.5)	5.1% (2.5-9.2)	7.6% (4.4-12.3)	10.6% (6.8-15.7)
CI = Confidence Interval					

Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Table 3. Distribution of Denominator Sizes and Measure Scores Across Physician Groups with ≥ 30 Beneficiaries

Across Physician Groups with ≥ 30 Beneficiaries	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5
Number of physician groups	73	73	73	73	73
Denominator size range (minimum-maximum)	30-260	30-571	30-315	30-512	30-416
Median denominator size	49	62	57	56	60
Measure score (95% CI) of the physician group with a denominator size closest to the median denominator size	2.0% (0.1-10.9)	8.1% (2.8-17.8)	8.8% (3.0-19.3)	12.5% (5.4-24.1)	23.3% (13.9-36.0)
Measure score range (minimum-maximum)	0.0%-5.7%	5.9%-8.5%	8.5%-10.7%	10.8%-13.9%	14.0%-41.5%
Median measure score	3.70%	7.14%	9.65%	12.24%	17.54%
Measure score (CI of the score) of the physician group with a score closest to the median score	3.7% (0.5-12.7)	7.1% (2.1-17.3)	9.6% (5.0-16.6)	12.2% (4.8-24.8)	17.5% (9.1-29.9)
95% CI based on using the median denominator size N=55	3.7% (0.5-12.6)	7.1% (2.0-17.4)	9.7% (3.5-20.7)	12.2% (5.2-23.9)	17.5% (9.0-30.2)
CI = Confidence Interval					

Table 4. Missing Days' Supply Analysis (All 8 States)

Test	Result
Percentage of beneficiaries in the denominator with one or more claims with missing days' supply	15/195,068 (0.01%)

Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Table 5. Commercial Discount Program Sensitivity Analysis (FL and RI)

Test	Result
Percentage of beneficiaries in the denominator who had no Part D claims for any drugs that are listed in the commercial discount prescription program during the measurement period (FL and RI)	6,906/88,895 (7.8%)
Percentage of beneficiaries with an antipsychotic on the Wal-Mart list and no Part D claims for any other drugs on the Wal-Mart formulary (FL and RI only)—referred to as flagged	490/88,895 (0.6%)
Measure rate assuming beneficiaries flagged have their last consecutive dispensing for each generic drug extended to the end of the measurement period	7,370/88,895 (8.3%)
Measure rate as originally calculated (FL and RI only)	7,330/88,895 (8.2%)

Table 6. Measure Value by State (All States)

	Denominator N	Numerator N	Measure Rate
Individuals with Clozapine Included	198,133	17,748	9.0%
Individuals with Clozapine Excluded	195,068	17,312	8.9%

Table 7. Measure Rate by State

	Denominator N	Numerator N	Measure Rate
All States	195,068	17,312	8.9%
AZ	17,793	1,133	6.4%
DE	3,570	293	8.2%
FL	82,298	6,707	8.2%
IA	14,926	1,611	10.8%
IN	28,751	2,971	10.3%
MS	17,675	1,456	8.2%
RI	6,597	623	9.4%
WA	23,458	2,518	10.7%

Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Table 7b. State Performance

Category	# of States	Mean	STD	10 th %ile	25 th %ile	50 th %ile	75 th %ile	90 th %ile
All States	8	9.0%	1.6%	6.4%	8.2%	8.8%	10.5%	10.8%

Table 8. Plan Performance

Category	# of Plans With Any Eligible Individuals	# of Plans With at Least 30 Individuals (%)	Mean	STD	10 th %ile	25 th %ile	50 th %ile	75 th %ile	90 th %ile
					10 th %ile	25 th %ile	50 th %ile	75 th %ile	90 th %ile
All plans	432	128 (29.6%)	5.9%	3.7%	2.1%	3.3%	5.1%	8.3%	10.6%
PDP	84	39 (46.4%)	8.0%	3.6%	2.9%	5.5%	8.4%	10.3%	11.4%
MA-PD	348	89 (25.6%)	5.0%	3.4%	1.4%	2.9%	4.4%	6.6%	8.8%

Table 9. Physician Group Performance

Category	# of Groups With Any Eligible Individuals (%)	# of Groups With at Least 30 Individuals (%)	Mean	STD	10 th %ile	25 th %ile	50 th %ile	75 th %ile	90 th %ile
					10 th %ile	25 th %ile	50 th %ile	75 th %ile	90 th %ile
All groups	3,656	365 (10.0%)	10.3%	5.9%	3.7%	6.5%	9.6%	13.2%	17.5%
AZ	399	11 (2.8%)	7.7%	3.9%	2.0%	5.9%	7.9%	10.5%	10.8%
FL	1,596	124 (7.8%)	9.9%	6.6%	2.8%	6.0%	8.8%	13.0%	17.8%
IA	244	46 (18.9%)	11.1%	4.8%	5.4%	8.3%	11.4%	13.9%	16.2%
IN	502	88 (17.5%)	11.4%	5.4%	5.3%	8.0%	10.0%	14.1%	18.9%
MS	267	35 (13.1%)	6.8%	3.8%	2.5%	3.9%	5.9%	9.8%	12.1%
RI	157	13 (8.3%)	13.6%	4.6%	9.4%	11.4%	12.8%	14.6%	21.8%
WA	388	39 (10.1%)	11.2%	5.7%	5.0%	7.7%	10.5%	13.3%	19.4%

Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Table 10. Measure Value by Age and Race/Ethnicity, Total Sample

Age Group	Denominator N	Numerator N	Measure Value
All Ages	195,068	17,312	8.9%
White	152,802	13,337	8.7%
African American	24,717	2,599	10.5%
Hispanic	12,787	898	7.0%
Other	4,762	478	10.0%
18 - 24	1,499	196	13.1%
White	1,053	135	12.8%
African American	263	42	16.0%
Hispanic	130	12	9.2%
Other	53	7	13.2%
25 - 44	35,171	4,869	13.8%
White	26,461	3,664	13.8%
African American	5,471	744	13.6%
Hispanic	1,991	257	12.9%
Other	1,248	204	16.3%
45 - 64	68,812	8,718	12.7%
White	54,249	6,861	12.6%
African American	10,001	1,336	13.4%
Hispanic	2,913	327	11.2%
Other	1,649	194	11.8%
65 - 74	30,541	1,920	6.3%
White	23,590	1,454	6.2%
African American	3,661	304	8.3%
Hispanic	2,627	121	4.6%
Other	663	41	6.2%
75 - 84	32,437	1,112	3.4%
White	25,440	838	3.3%
African American	3,274	131	4.0%
Hispanic	3,046	116	3.8%
Other	677	27	4.0%
85 +	26,608	497	1.9%
White	22,009	385	1.8%
African American	2,047	42	2.1%
Hispanic	2,080	65	3.1%
Other	472	5	1.1%

Attachment B: Measure Result Tables

Measure QP-4: Polytherapy with Oral Antipsychotics

Table 11. Measure Value by Dual-Eligible Status and Age, Total Sample

Category	Denominator N	Numerator N	Measure Value
Dual-Eligible	143,370	14,949	10.4%
18 - 24	1,362	182	13.4%
25 - 44	30,378	4,393	14.5%
45 - 64	54,468	7,545	13.9%
65 - 74	20,409	1,601	7.8%
75 - 84	20,267	867	4.3%
85 +	16,486	361	2.2%
Not Dual-Eligible	51,698	2,363	4.6%
18 - 24	137	14	10.2%
25 - 44	4,793	476	9.9%
45 - 64	14,344	1,173	8.2%
65 - 74	10,132	319	3.2%
75 - 84	12,170	245	2.0%
85 +	10,122	136	1.3%

Table 12. Measure Value by Gender and Age, Total Sample

Category	Denominator N	Numerator N	Measure Value
Female	117,514	8,350	7.1%
18 - 24	494	62	12.6%
25 - 44	15,695	1,827	11.6%
45 - 64	36,549	4,060	11.1%
65 - 74	19,840	1,175	5.9%
75 - 84	23,297	804	3.5%
85 +	21,639	422	2.0%
Male	77,554	8,962	11.6%
18 - 24	1,005	134	13.3%
25 - 44	19,476	3,042	15.6%
45 - 64	32,263	4,658	14.4%
65 - 74	10,701	745	7.0%
75 - 84	9,140	308	3.4%
85 +	4,969	75	1.5%

Attachment C - Measure Algorithm

Measure QP-4: Polytherapy with Oral Antipsychotics

Denominator: Individuals who were prescribed at least one routinely scheduled oral antipsychotic medication during the measurement period (Attachment A — Table 1).

A routinely scheduled antipsychotic medication, as designated by the unique generic name or 10 digit generic product identifier (GPI), is one having at least 2 consecutive dispensings of at least 25 days supply for each dispensing. Consecutive is defined as having a medication possession ratio (MPR) of at least 0.8. The MPR is calculated as the days supply of the first dispensing divided by the difference in days between the first fill date and the next fill date.

1. Include individuals 18 or older as of December 31st of the measurement year.
2. Include individuals who were continuously enrolled in Part D, meaning they have no more than a one-month gap in enrollment during the measurement year.
3. Exclude individuals who died during the measurement year.
4. Pull all Part D claims for antipsychotics during the current measurement year.
5. Pull the generic name or GPI from the NDC file used to create the antipsychotic format into the Part D claims file from step 4.
6. Merge the antipsychotics Part D claims file with the eligibility file from step 3 to create a dataset with all Part D claims for eligible individuals.
7. Include individuals who had at least 1 routinely scheduled oral antipsychotic medication (2 consecutive dispensings of at least a 25 days supply each) during the measurement year:
 - a) Sort the dataset by individual HIC number (bene_clm_num_curr_xref), generic name or GPI, fill date (rx_service_dt), and descending days supply.
 - b) De-duplicate by individual HIC number (bene_clm_num_curr_xref), generic name or GPI, and fill date (rx_service_dt), keeping the antipsychotic claim with the largest days supply if there are multiple prescribed on the same date of service.
 - c) Keep only claims for individuals that have at least one antipsychotic medication with at least two dispensing each (with at least 25 days supply each)
 - d) For each individual and generic name or GPI, calculate the MPR (as defined above) for all of the dispensings.
 - e) If the MPR ≥ 0.8 , then flag the claim as “consecutive claim” and keep the individual in the denominator

- f) Exclude individuals who did not have at least 1 medication (generic name) with 2 consecutive 25+ days supply claims/dispensings during the measurement year.
- 8. Exclude individuals who received clozapine during the measurement year.

Numerator: Individuals in the denominator who are prescribed 2 or more concurrent routinely scheduled antipsychotic medications.

Concurrent therapy is defined as use of one routinely scheduled oral antipsychotic medication that overlaps with the use of another (different generic name) scheduled oral antipsychotic medication by at least 90 days.

1. Keep the Part D claims for the routinely scheduled oral antipsychotic medications for the individuals identified in the denominator. Make sure the dataset is still sorted by individual HIC number (bene_clm_num_curr_xref), generic name or GPI, and fill date (rx_service_dt).
2. Exclude the individuals who only have one routinely scheduled oral antipsychotic medication during the measurement period.
3. Create a start date and end date for each period of consecutive therapy for each oral antipsychotic medication (generic name): See example table.
 - a) The start date is the fill date of the first dispensing of an antipsychotic medication.
 - b) The next dispensing is added to the period of therapy if the MPR is ≥ 0.8 (consecutive).
 - c) This continues until the MPR is not ≥ 0.8 . If the MPR is not ≥ 0.8 (not consecutive), then the end date of the consecutive therapy period is the fill date + days supply for the last consecutive dispensing prior to the nonconsecutive dispensing.
 - d) The start date for the next consecutive therapy period of the same antipsychotic (generic name or GPI) is the fill date of the first dispensing that occurred after the last consecutive therapy period.
 - e) Repeat Steps 3b) & 3c) to calculate the end date next consecutive therapy period.
 - f) Continue this method until the last dispensing is reached. If the end date is calculated to be after the end of the current measurement year, then the end date is the last day of the measurement period.


Each individual may have multiple consecutive therapy periods for a given oral antipsychotic (generic name or GPI).

Example: Numerator Step 3

ID	Antipsychotic Drug	Next Fill Date	Next Days Supply	Previous Fill date	Previous Days supply	MPR	Consecutive (MPR ≥ 0.8)	Start Date	End Date	Consecutive Therapy Period
Bene1	DrugA	1/8/08	30				N	1/8/08 (3a)		1
Bene1	DrugA	2/6/08	30	1/8/08	30	1.03	Y	1/8/08	3/7/08 (3b)	1
Bene1	DrugA	3/4/08	30	2/6/08	30	1.11	Y	1/8/08	4/3/08	1
Bene1	DrugA	3/6/08	30	3/4/08	30	15	Y	1/8/08	4/5/08	1
Bene1	DrugA	3/24/08	30	3/6/08	30	1.67	Y	1/8/08	4/23/08 (3c)	1
Bene1	DrugA	7/17/08	30			0.52 (3c)	N	7/17/08 (3d)		2
Bene1	DrugA	8/4/08	30	7/17/08	30	1.67	Y	7/17/08	9/3/08	2
Bene1	DrugA	10/2/08	30			0.51	N	10/2/08		3
Bene1	DrugA	11/3/08	30	10/2/08	30	0.94	Y	10/2/08	12/3/08	3
Bene1	DrugA	11/29/08	30	11/3/08	30	1.15	Y	10/2/08	12/29/08	3
Bene1	DrugA	12/29/08	30	11/29/08	30	1	Y	10/2/08	12/31/08 (3f)	3

4. For each individual, compare each consecutive period of therapy of an antipsychotic medication with the consecutive periods of therapy for each of the other antipsychotic medications to calculate overlap days. In the example below, you would compare the period of consecutive therapies for Drug A vs. Drug B, Drug B vs. Drug C, and Drug A vs. Drug C.

Example: Periods of consecutive therapies for 3 antipsychotics for 1 individual



5. Keep those individuals that had at least one occurrence of two different antipsychotic drugs that overlapped for at least 90 days during the measurement period.

Part D Plan Attribution:

The following is intended as guidance and reflects only one of many methodologies for assigning individuals to a Part D Plan.

1. Count Part D claims per individual per Part D Plan (contract number) for all individuals enrolled in Part D during the measurement year.
2. Attribute the individual to the plan with the maximum number of Part D claims. If a tie exists, attribute the individual to the plan that submitted the most recent claim.
3. Attach the Part D plan contract number to the denominator and numerator files by individual.

Physician Group Attribution:

Physician group attribution was adapted from *Generating Medicare Physician Quality Performance Measurement Results (GEM) Project: Physician and Other Provider Grouping and Patient Attribution Methodologies* (www.cms.gov/GEM). The following is intended as guidance and reflects only 1 of many methodologies for assigning individuals to a medical group. Please

note that the physician group attribution methodology excludes patients that died even though the overall measure does not.

I. Identify Physician and Medical Groups

1. Identify all Tax Identification Numbers (TIN)/ National Provider Identification (NPI)/UPIN combinations from all Part B claims in the measurement year and the prior year. The NPI is for the performing provider is used.

If no NPI is available on the claim, check other data sources such as CMS provider tables or the National Plan and Provider Enumeration System (NPPES), for a current NPI based on the physician UPIN. Keep records with valid NPI. Valid NPIs have 10 numeric characters (no alpha characters).

Note: Due to NPI implementation, UPINs are not necessary for attribution using Part B data from 2008 and later.

2. For valid NPIs, pull credentials and specialty code(s). Credentials and specialty codes are pulled in the following order.
 - a. From the CMS provider tables
 - b. If not found in A, then pull from NPPES.
3. Create 1 record per NPI with all credentials and all specialties. A provider may have more than 1 specialty.
4. Attach TIN to NPI, keeping only those records with credentials indicating a physician (MD or DO), physician assistant (PA), or nurse practitioner (NP).
5. Identify Medical group TINs: Medical group TINs are defined as TINs that had at least one physician, physician assistant, or nurse practitioner provider specialty codes on at least 50% of Part B carrier claim line items billed by the TIN during the measurement year or prior year. The provider specialty codes are listed in Table A.
 - a. Pull Part B records billed by TINs identified in #4 during the measurement year and prior year.
 - b. Identify claims that had the performing NPI (npi_prfrm) in the list of eligible physicians/TINs. Keeping those that match by TIN, performing NPI, and provider state code;
 - c. Calculate the percent of Part B claims that Match by TIN, npi_prfrm, and provider state code for each TIN, keeping those TINs with percent greater or equal to 50%;

- d. Delete invalid TINs. Examples of invalid TINs are defined as having the same value for all 9 digits or values of 012345678 , 012345678, 123456789, 987654321, 87654321
6. Identify TINs that are not solo practices
 - a. Pull Part B records billed by physicians identified in #4 for the measurement year and/or prior year. If the performing NPI is not on the claim, match to obtain NPI from the list created in #4 by UPIN
 - b. Count unique NPIs per TIN;
 - c. Keep only those TINs 2 or more providers.
 - d. Delete invalid TINs. Examples of invalid TINs are defined as having the same value for all 9 digits or values of 012345678 , 012345678, 123456789, 987654321, 87654321
7. Create final group of TINs from #5 and #6 (TINs that are medical group and are not solo practices).
8. Create file of TIN and NPIs associated with those TINs. These are now referred to as the medical group TIN.

II. Identify Individual Sample and Claims

9. Create Individual Sample
 - a. Pull individuals with 11+ months of Pt A, B, & D during the measurement year
 - b. Verify the individual did not have any months with Medicare as secondary payor.
Remove individuals with BENE_PRMRY_PYR_CD not in
 - A=working aged beneficiary/spouse with EGHP
 - B=ESRD in the 18 month coordination period with an employer group health plan
 - G= working disabled for any month of the year.
 - c. Verify the individual resides in the US, Puerto Rico, Virgin Islands or Washington D.C.
 - d. Exclude individuals that enter the Medicare Hospice at any point during the measurement year.
 - e. Exclude individuals that died during the measurement year
10. For individuals identified in #9, pull office visit claims that occur in during the measurement year and in the 6 months prior to the measurement year.
 - a. Office visit claims have CPT codes of 99201-99205, 99211-99215 and 99241-99245.
 - b. Exclude claims with no Physician_upin and no npi_prfrmng
11. Attach medical group TIN to claims by NPI or UPIN if no performing NPI is available.

III. Patient Attribution:

12. Pull all Part B office claims from #11 with specialties indicating primary care or psychiatry (Table A). Attribute each individual to at most 1 medical group TIN for each measure.

- a. Evaluate specialty on claim (HSE_B_HCFA_PRVDR_SPCLTY_CD) first. If specialty on claim does not match any of the measure-specific specialties, then check additional specialty fields.
 - b. If the provider specialty indicates nurse practitioners or physician assistants ('50' '97'), then check additional specialty codes
13. For each individual, count claims per medical group TIN. Keep only individuals with 2 or more E&M claims.
14. Attribute individual to the medical group TIN with the most claims. If a tie occurs between medical group TINs, attribute the TIN with most recent claim.
15. Attach the medical group TIN to the denominator and numerator files by individual.

Table A. Provider specialties and specialty codes to include only physician, physician assistants, and nurse practitioners for physician grouping, TIN selection, and patient attribution

Provider Specialty Codes	Provider Specialty
01	General practice*
08	Family practice*
11	Internal medicine*
16	Obstetrics/gynecology*
38	Geriatric medicine*
70	Multi-specialty clinic or group practice*
84	Preventive medicine*
02	General surgery
03	Allergy/immunology
04	Otolaryngology
05	Anesthesiology
06	Cardiology
07	Dermatology
09	Interventional Pain Management
10	Gastroenterology
12	Osteopathic manipulative therapy
13	Neurology
14	Neurosurgery
18	Ophthalmology
20	Orthopedic surgery

Provider Specialty Codes	Provider Specialty
22	Pathology
24	Plastic and reconstructive surgery
25	Physical medicine and rehabilitation
26	Psychiatry*
28	Colorectal surgery
29	Pulmonary disease
30	Diagnostic radiology
33	Thoracic surgery
34	Urology
36	Nuclear medicine
37	Pediatric medicine
39	Nephrology
40	Hand surgery
44	Infectious disease
46	Endocrinology
50	Nurse practitioner*
66	Rheumatology
72	Pain Management
76	Peripheral vascular disease
77	Vascular surgery
78	Cardiac surgery
79	Addiction medicine
81	Critical care (intensivists)
82	Hematology
83	Hematology/oncology
85	Maxillofacial surgery
86	Neuropsychiatry*
90	Medical oncology
91	Surgical oncology
92	Radiation oncology
93	Emergency medicine
94	Interventional radiology
97	Physician assistant*
98	Gynecologist/oncologist
99	Unknown Physician Specialty
Other	NA

*Provider specialty codes specific to this measure